Investigating the genetic relationship between depression symptoms and Alzheimer's Disease in clinically diagnosed and proxy cases

4

33

Lachlan Gilchrist^{a,b,c}, Thomas P. Spargo^{a,d,e}, Rebecca E. Green^f, Jonathan R.I. Coleman^{b,e}, 5 6 David M. Howard^b, Jackson G. Thorp^g, Brett Adey^b, Jodie Lord^a, Helena L. Davies^b, Jessica 7 Mundy^b, Molly R. Davies^{b,e}, Christopher Hübel^{b,e}, Shannon Bristow^{b,e}, Sang Hyuck Lee^{b,e}, 8 Henry Rogers^{b,e}, Charles Curtis^{b,e}, Gursharan Kalsi^{b,e}, Ryan Arathimos^b, Anne Corbett^h, Clive 9 Ballard^h, Helen Brooker^h, Byron Creese^h, Dag Aarslandⁱ, Adam Hampshire^j, Latha 10 Velayudhanⁱ, Thalia C. Eley^{b,e}, Gerome Breen^{b,e}, Alfredo Iacoangeli^{d,a,e}, Sulev Koks^{c,k}, Cathryn 11 M. Lewis^{b,I}, Petroula Proitsi^{a*} on behalf of the Alzheimer's Disease Neuroimaging Initiative, 12 AddNeuroMed, and GERAD1 Consortium 13 14 ^a Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom 15 ^b Social, Genetic and Developmental Psychiatry, King's College London, London, United Kingdom 16 ^c Perron Institute for Neurological and Translational Science, Perth, Australia 17 ^d Department of Biostatistics and Health Informatics, King's College London, London, United Kingdom 18 • NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust 19 and King's College London, King's College London, London, United Kingdom 20 ^fMRC Unit for Lifelong Health and Aging, University College London, London, United Kingdom 21 9 Translational Neurogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, 22 Australia 23 ^h College of Medicine and Health, University of Exeter, Exeter, United Kingdom 24 ⁱOld Age Psychiatry, King's College London, London, United Kingdom 25 Faculty of Medicine, Department of Brain Sciences, Imperial College London, London, United Kingdom 26 ^k Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia 27 Department of Medical and Molecular Genetics, King's College London, London, United Kingdom 28 29 30 * Corresponding author: Dr. Petroula Proitsi (petroula.proitsi@kcl.ac.uk) 31 32

- 34
- 35 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36

Abstract

37 Depression is a risk factor for the later development of Alzheimer's disease (AD), but 38 evidence for their genetic relationship is mixed. Assessing depression symptom 39 specific genetic associations may better clarify this relationship.

40

Using data from the UK Biobank, the GLAD Study and PROTECT, we performed the 41 largest genome-wide meta-analyses (GWAS) of the nine depression symptom items, 42 plus their sum score, on the Patient Health Questionnaire (PHQ-9) (GWAS equivalent 43 N: 224,535–308,421). We then assessed global and local genetic correlations and 44 statistical colocalisation between depression/depression symptoms and AD across six 45 AD GWAS with varying proportions of clinical and proxy (family history) case 46 ascertainment. We assessed bi-directional causal associations using Mendelian 47 randomisation (MR) and tested the predictive utility of depression/depression 48 symptom polygenic risk scores (PRS) for AD case/control status in three clinical AD 49 50 cohorts.

51

Our GWAS meta-analyses identified 37 genomic risk loci across the ten depression 52 symptom phenotypes. Of the 72 global genetic correlation tests conducted between 53 54 depression/depression symptoms and AD, 20 were significant at $p_{FDR} \leq 0.05$. Only one of these was identified with AD GWAS containing clinical-only cases. Local genetic 55 correlations were detected at 14 loci. Statistical colocalisation was not identified at 56 57 these loci but was identified in the region of transmembrane protein 106B (TMEM106B) between multiple depression phenotypes and both clinical-only and 58 clinical+proxy AD. MR and PRS analyses did not vield significant results after multiple 59 testing correction. 60

61

Our findings do not demonstrate a causal role of depression/depression symptoms on
AD and suggest that previous evidence of genetic overlap between depression and
AD may be driven by the inclusion of family-history-based proxy cases/controls.
However, the identification of colocalisation at TMEM106B warrants further
investigation.

67

68 1. INTRODUCTION

Epidemiological studies suggest that a diagnosis of depression is a risk factor for the
later development of dementia¹⁻⁶, of which Alzheimer's disease (AD) is the most
common form, accounting for approximately 80% of the over 40 million global cases⁷.
Establishing the underlying mechanisms by which depression confers increased risk
for AD offers a pathway by which new interventions might be implemented and the
global dementia burden reduced⁸.

75 As twin studies have demonstrated, both depression and AD are substantially heritable – approximately 40% and 80% respectively^{9,10}. Further, large-scale genome-76 77 wide association studies (GWAS) have demonstrated high polygenicity, identifying over 70 genomic risk loci for AD and nearly 200 for depression^{11–17}. It is therefore 78 79 possible that their phenotypic association is in part due to shared genetic architecture. However, results from previous investigations into the genetic overlap 80 81 between the two disorders have been mixed. For example, some findings indicate non-significant genetic overlap^{18,19}, others a significant - if modest - genetic 82 correlation of ~16-17% and a risk increasing causal effect of depression on AD²⁰⁻²². 83

84 According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-85 5), diagnosis of a major depressive episode requires the presence of at least five of 86 a possible nine symptoms for ≥ 2 weeks, including one of the two cardinal symptoms - depressed mood or anhedonia²³. Potentially hundreds of symptom combinations 87 are possible to meet this diagnosis criteria²⁴⁻²⁶. As such, this heterogeneity poses 88 challenges to researchers seeking to better understand differences in the genetic 89 contribution to depression and its subtypes^{27,28}. However, the decomposition of 90 91 depression into individual symptoms has provided insight into unique patterns of genome-wide significant loci and cross-trait genetic associations, as demonstrated 92 93 in a recent GWAS of depression symptoms on the Patient Health Questionnaire (PHQ-9) by Thorp et al.²⁹. 94

A number of studies suggest that anhedonia may be a better predictor of dementia than depressed mood³⁰⁻³². Further, several depression symptoms, such as appetite changes, psychomotor dysfunction, and sleep disruption are commonly observed in non-depressed dementia patients³³⁻³⁵. Taking this into account alongside the mixed nature of previous findings examining the genetic overlap between depression and AD, it is possible that leveraging depression symptom level genetic information may offer greater insight into the disorders shared genetic architecture.

However, any association between depression and AD must also consider the
 potential influence of differences in case/control ascertainment in AD GWAS. A review
 by Escott-Price et al.³⁶ notes that recent large-scale AD GWAS contain a relatively
 small proportion of clinically ascertained cases/controls, with a large percentage of

cases ascertained by proxy – that is, cases and controls are defined as individuals with and without a self-reported parental history of AD/dementia, respectively. The combination of clinical and proxy samples in AD GWAS meta-analyses has proved an effective way of boosting sample size and variant discovery^{15–17,37}. However, evidence suggests that this has come at the expense of specificity in regard to genomic risk loci and an apparent stagnation in the percentage of variance explained by common variants³⁶. Most importantly for cross-trait analysis, recent studies indicate that the direction of Mendelian Randomisation (MR) causal estimates for AD risk factors on AD can be in the opposite direction depending on whether the AD outcome GWAS contains clinical and proxy cases/controls or is more strictly clinically ascertained^{38–40}.

To address these points, we perform the first and largest genome-wide meta-analyses of PHQ-9 depression symptom items using data from the Genetic Links to Anxiety and Depression (GLAD) Study⁴¹, the PROTECT Study^{42,43} and two questionnaires from UK Biobank (UKB)⁴⁴. We obtained summary statistics from previous large-scale GWAS for clinical¹¹ and broad¹² depression, and six AD GWAS. Specifically, three with clinical+proxy case/control ascertainment¹⁵⁻¹⁷, one with proxy-only³⁷, and two with clinical-only^{14,45}. We used these GWAS to assess the presence, strength and differences in genetic overlap between depression, depression symptoms and AD, with the additional aim of better understanding the influence of different AD case ascertainment strategies on associations.

142 2. METHODS

143 For an analysis flowchart, see Figure 1.




Figure 1: Analysis flowchart for the present study describing the analyses undertaken following genetic and phenotypic quality control (see: Methods) for each of the depression symptom items of the Patient Health Questionnaire (PHQ-9) in each of the four samples – UK Biobank (Mental Health Questionnaire and Experience of Pain Questionnaire), the Genetic Links in Anxiety and Depression (GLAD) Study and the PROTECT Study. GWAS = Genome-wide association analysis; AD = Alzheimer's Disease; MTAG = Multi-trait Analysis of GWAS; FUMA = Functional Mapping and Annotation; LAVA = Local Analysis of [co]Variant Association; ADNI = Alzheimer's Disease Neuroimaging Initiative; PC = genetic principal components

2.1 GWAS in the UK Biobank, GLAD and PROTECT

2.1.1 Patient Health Questionnaire-9 (PHQ-9) phenotypes

The PHQ-9 is a well-validated clinical screening questionnaire used to assess depression symptom severity on nine individual symptoms in the DSM-IV^{46,47}. The severity of each symptom is measured by the self-reported persistence of that symptom over the preceding two weeks on a scale of 0 to 3. Scores of 3 indicate an individual experienced that symptom nearly every day, 2 indicates an individual experienced that symptom more than half the days, 1 indicates an individual experienced that symptom for several days and 0 indicates no experience of that symptom at all. The sum of an individual's scores over all nine items (sum-score) ranges from 0-27. For an overview of the PHQ-9 items and response distribution for each sample, see **Table 1**. Sum-score distributions can be seen in **Supplementary** Table 1.

183
184
185
186

	PHQ-9 Question:				PHQ-9 Response				
Depression Symptom	How often in the last 2 weeks have you been bothered by any of the following problems?	UK Biobank Data Field (MHQ/EoP)	Cohort	0 (Not at all)	1 (Several days)	2 (more than half the days)	3 (Nearly every day)		
			UK Biobank (MHQ)	117045 (81.75%)	21088 (14.73%)	2965 (2.07%)	2073 (1.45%)		
			UK Biobank (EoP)	116330 (76.07%)	29743 (19.45%)	4115 (2.69%)	2744 (1.79%)		
Anhedonia	Little interest or pleasure in doing things	20514/120104	GLAD	4108 (27.08%)	6429 (42.31%)	2502 (16.49%)	2142 (14.12%)		
			PROTECT	6194 (81.62%)	1130 (14.89%)	127 (1.67%)	138 (1.82%)		
			Total	243677 (76.42%)	58380 (18.31%)	9709 (3.04%)	7097 (2.23%)		
			UK Biobank (MHQ)	117505 (82.07%)	18521 (12.94%)	3860 (2.70%)	3285 (2.29%)		
			UK Biobank (EoP)	121071 (79.17%)	22432 (14.67%)	5404 (3.53%)	4025 (2.63%)		
Appetite Changes	Poor appetite or overeating	20511/120108	GLAD	4242 (27.96%)	4459 (29.39%)	3057 (20.15%)	3413 (22.50%)		
			PROTECT	6364 (83.86%)	971 (12.79%)	145 (1.91%)	109 (1.44%)		
			Total	249182 (78.15%)	46383 (14.55%)	12466 (3.90%)	10832 (3.40%)		
			UK Biobank (MHQ)	117951 (82.07%)	20386 (14.24%)	2713 (1.89%)	2121 (1.48%)		
	Trouble concentrating on things		UK Biobank (EoP)	123920 (81.03%)	23441 (15.33%)	3258 (2.13%)	2313 (1.51%)		
Concentration Problems		20508/120110	GLAD	4665 (30.75%)	5200 (34.28%)	2891 (19.06%)	2415 (15.92%)		
			PROTECT	6374 (83.99%)	1022 (13.47%)	116 (1.53%)	77 (1.01%)		
			Total	252910 (79.32%)	50049 (15.70%)	8978 (2.82%)	6926 (2.17%)		
	Feeling down, depressed, or hopeless		UK Biobank (MHQ)	112187 (78.36%)	26516 (18.52%)	2690 (1.88%)	1778 (1.24%)		
			UK Biobank (EoP)	119004 (77.81%)	28914 (18.91%)	2998 (1.96%)	2016 (1.32%)		
Depressed Mood		20510/120105	GLAD	3595 (23.70%)	6746 (44.47%)	2538 (16.73%)	2292 (15.11%)		
			PROTECT	6108 (80.48%)	1329 (17.51%)	92 (1.21%)	60 (0.79%)		
			Total	240894 (75.55%)	63505 (19.92%)	8318 (2.61%)	6146 (1.93%)		
	Feeling tired or having little energy		UK Biobank (MHQ)	71903 (50.39%)	56170 (39.23%)	7595 (5.30%)	7503 (5.24%)		
			UK Biobank (EoP)	74733 (48.87%)	61571 (40.26%)	8820 (5.77%)	7808 (5.11%)		
Fatigue		20519/120107	GLAD	1335 (8.80%)	4971 (32.77%)	3530 (23.27%)	5335 (35.17%)		
			PROTECT	3715 (48.95%)	3164 (41.69%)	359 (4.73%)	351 (4.63%)		
			Total	151686 (47.57%)	125876 (39.48%)	20304 (6.37%)	20997 (6.58%)		
	Feeling bad about yourself – or that you are a failure or have let yourself or your family down	20507/120109	UK Biobank (MHQ)	116091 (81.09%)	21503 (15.02%)	2878 (2.01%)	2699 (1.89%)		
			UK Biobank (EoP)	123702 (80.89%)	22756 (14.88%)	3399 (2.22%)	3075 (2.01%)		
Feelings of Inadequacy			GLAD	3986 (26.27%)	5131 (33.82%)	2800 (18.46%)	3254 (21.45%)		
			PROTECT	6095 (80.31%)	1260 (16.60%)	128 (1.69%)	106 (1.40%)		
			Total	249874 (78.36%)	50650 (15.88%)	9205 (2.89%)	9134 (2.86%)		
	Moving or speaking so slowly that other	20518/120111	UK Biobank (MHQ)	135592 (94.71%)	5805 (4.05%)	1025 (0.72%)	749 (0.52%)		
	people could have noticed, or the oppisite – being so fidity or restless that you have been moving around a lot more than usual		UK Biobank (EoP)	141662 (92.63%)	8285 (5.42%)	1676 (1.10%)	1309 (0.86%)		
Psychomotor Changes			GLAD	9932 (65.47%)	3254 (21.45%)	1215 (8.01%)	770 (5.08%)		
			PROTECT	7363 (97.02%)	182 (2.40%)	22 (0.29%)	22 (0.29%)		
			Total	294549 (92.37%)	17526 (5.5%)	3938 (1.24%)	2850 (0.89%)		
			UK Biobank (MHQ)	73219 (51.14%)	48936 (34.18%)	10007 (6.99%)	11009 (7.69%)		
	Trouble falling asleep or staying asleep, or sleeping too much	20517/120106	UK Biobank (EoP)	70799 (46.29%)	56955 (37.24%)	12245 (8.01%)	12933 (8.46%)		
Sleep Problems			GLAD	2577 (16.99%)	5043 (33.24%)	3173 (20.91%)	4378 (28.86%)		
			PROTECT	3708 (48.86%)	2749 (36.22%)	570 (7.51%)	562 (7.41%)		
			Total	150303 (47.14%)	113683 (35.65%)	25995 (8.15%)	28882 (9.06%)		
Suicidal Thoughts	Thoughts you would be better off dead or of hurting yourself in some way	-	UK Biobank (MHQ)	137381 (95.96%)	4801 (3.35%)	566 (0.40%)	423 (0.30%)		
			UK Biobank (EoP)	146843 (96.02%)	4880 (3.19%)	686 (0.45%)	523 (0.34%)		
			GLAD	9116 (60.09%)	3713 (24.47%)	1215 (8.01%)	1127 (7.43%)		
			PROTECT	7392 (97.40%)	172 (2.27%)	13 (0.17%)	12 (0.16%)		
			Total	300732 (94.31%)	13566 (4.25%)	2480 (0.78%)	2085 (0.65%)		

Table 1: Patient Health Questionnaire (PHQ-9) derived depression symptom phenotypes, their
 corresponding question on the PHQ-9, and the distribution and percentage of responses for each of

190 *the four samples on which genome-wide association analysis was performed.*

192

193 2.1.2 Study population

In each GWAS sample, individuals were only retained if they had reported European
ancestry and had provided a valid response to all PHQ-9 items. Individuals were
excluded if they had reported a previous professional diagnosis of schizophrenia,
psychosis, mania, hypomania, bipolar, or manic depression (UKB Field ID: 20544) or
a previous prescription of medication for a psychotic experience (UKB Field ID:
20466).

200 2.1.3 GWAS software

All GWAS were conducted using REGENIE v3.1.3⁴⁸. In step one of REGENIE, ridge 201 regression is applied to a subset of quality controlled (QC'd) variants to fit, combine 202 203 and decompose a set of leave-one-chromosome-out (LOCO) predictions. QC for step 204 one was undertaken using PLINK v1.949. In step two, imputed variants are tested for 205 association with the phenotype. LOCO predictions from step one are included as 206 covariates to control for proximal contamination. For all GWAS, genotyping batch, sex, age, and age-squared were included as covariates, as were the maximum 207 208 available genetic principal components (PCs) for GLAD (10 PCs) and PROTECT (20 209 PCs) to control for population stratification. For the UK Biobank analyses, 16 PCs were included as recommended by Privé et al.⁵⁰. Assessment centre was also included as 210 a covariate for UK Biobank analyses. 211

A total of 40 GWAS were conducted for the meta-analyses – one for each of the nine PHQ-9 depression symptom phenotypes as well as the sum-score across all nine items in each of the four samples. To maximise statistical power, PHQ-9 phenotypes were treated as continuous (ranging 0-3 for individual items and 0-27 for the sum score) and analysed using linear regression. GWAS were restricted to the autosomes.

218

2.1.4 GWAS: UK Biobank (UKB)

UKB is a large-scale biomedical database and research resource consisting of ~500,000 individuals with data across a broad range of phenotypes, including mental health outcomes⁴⁴. Individuals in UKB have been genotyped on the custom UK
Biobank Axiom or UKBiLEVE arrays, with imputed data available for ~90 million variants imputed with IMPUTE2 using the Haplotype Reference Consortium (HRC)⁵¹ and combined UK10K + 1000 Genomes Phase 3 reference panels⁵².

UKB participants have completed the PHQ-9 in two online surveys. In total, 157,345 individuals provided responses as part of the Mental Health Questionnaire (UKB-MHQ) (Category: 136) between 2016 and 2017, and 167,199 individuals had provided responses as part of the Experience of Pain Questionnaire (UKB-EoP) (Category: 154) between 2019 and 2020.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and 230 previous diagnosis/prescription exclusions, 144,630 (UKB-MHQ) and 155,027 (UKB-231 EoP) individuals remained prior to genetic QC for REGENIE. In step one, single-232 233 nucleotide polymorphisms (SNPs) with a call rate > 98%, minor allele frequency (MAF) > 1%, and Hardy-Weinberg equilibrium test $p > 1 \times 10^{-8}$ were retained, as were 234 individuals with variant missingness < 2%, no unusual levels of heterozygosity, and 235 not mismatched on sex. Individuals were retained if they were determined to be of 236 237 European ancestry based on 4-means clustering on the first two principal 238 components.

For the final GWAS analyses, 143,171 (mean age [SD] = 63.70 [7.68]; %female = 56.38%) and 152,932 (mean age [SD] = 65.95 [7.63]; %female = 56.57%) individuals proceeded from the MHQ and EoP questionnaires respectively. Of these, 108,601 individuals had provided responses on both questionnaires. In step two, a total of 9,746,698 imputed variants were retained with MAF \ge 0.01 and imputation INFO score \ge 0.7.

245

2.1.5 GWAS: Genetic Links to Anxiety and Depression (GLAD) Study

The GLAD study has the specific goal of recruiting a large cohort of re-contactable
individuals with anxiety or depression into the National Institute for Health and Care
Research (NIHR) Mental Health BioResource with genetic, environmental and
phenotypic data collected⁴¹. Genotyping for GLAD was conducted using the UK
Biobank v2 Axiom array and imputed using the TopMed imputation pipeline⁵³.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and 251 252 previous diagnosis/prescription exclusions, 15,472 individuals remained prior to 253 genetic QC for REGENIE step one. Genotype data was provided by the study team 254 and had been filtered to retain SNPs with a genotype call rate > 95%, MAF > 1%, Hardy-Weinberg equilibrium test $p > 1 \times 10^{-10}$, and individuals with genotype 255 missingness < 5%. Individuals were additionally excluded if they had unusual levels 256 of heterozygosity, mismatched on sex and of non-European ancestry based on 4-257 means clustering. A total of 15,171 individuals (mean age [SD] = 39.27 [14.61]; 258 259 % female = 78.30%) were retained for the final analysis. In step two, a total of 13,979,187 imputed variants with MAF \geq 0.001 and INFO \geq 0.7 were analysed. 260

261

2.1.6 GWAS: PROTECT Study

PROTECT is an online registry of ~25,000 UK-based individuals that aims to track
cognitive health in older adults. Individuals were only considered eligible for inclusion
in PROTECT if they were older than 50, had no previous dementia diagnosis and had
internet access. Genetic data are available alongside phenotypic data for ~10,000 of
the participants. These individuals were genotyped on the Illumina Infinium Global

267 Screening Array and imputed on the 1000 Genomes reference panel⁵⁴ using the
268 Michigan imputation server and genotype phasing using Eagle.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and previous diagnosis/prescription exclusions, 7,589 individuals remained for genetic QC for step one of REGENIE. Genetic data in PROTECT had been previously QC'd prior to imputation to only retain individuals and variants with a call rate > 98%, Hardy-Weinberg equilibrium test p > 0.00001 and excluding unusual heterozygosity⁴². Variants used in step one were down-sampled from the imputed data using a snplist from the Illumina Infinium Global Screening Array provided by the PROTECT investigators. Variants were retained if they had MAF > 1%. After mismatched sex and 4-means clustering ancestry exclusions, a total of 7,589 individuals (mean age [SD] = 61.96 [7.07]; %female = 75.13%) proceeded to step two. In step two, 9,388,534 imputed variants with MAF \geq 0.001 and imputation INFO score \geq 0.7 were analysed.

301 2.2 GWAS summary statistics

An overview of additional summary statistics obtained for this study can be seen inTable 2.

Phenotype (Original GWAS)	Excluded Samples	Cases (% Clinical)	Controls (% Clinical)	Total	SNP h2 (SE)
Depression GWAS					
Broad Depression		170,756	329,443		0.0798
(Howard et al. (2019))	23andMe	(25.3%)	(29.0%)	500,199	(0.003)
Clinical Depression	UK Biobank;	45,591	97674		0.1012
(Wray et al. (2018))	23andMe	(100%)	(100%)	143,261	(0.007)
Alzheimer's Disease GWAS					
Clinical + Proxy AD		85,934	401,577		0.0306
(Bellenguez et al. (2022) (Stage 1))	N/A	(45.5%)	(14.0%)	487,511	(0.003)
Clinical + Proxy AD		86 <i>,</i> 531	676,386		0.0237
(Wightman et al. (2021))	23andMe	(46.1%)	(26.1%)	762,917	(0.004)
Clinical + Proxy AD		71,880	383,378		0.0234
(Jansen et al. (2019))	N/A	(33.5%)	(14.4%)	455,258	(0.003)
Proxy-only AD		42,035	272,243		0.0165
(Marioni et al. (2018))	IGAP	(0%)	(0%)	314,278	(0.003)
Clinical-only AD	UK Biobank;	39,918	358,140		0.0431
(Wightman et al. (no UKB) (2021))	23andMe	(100%)	(29.1)	398,058	(0.008)
Clinical-only AD		21,982	41,944		0.068
(Kunkle et al. (2019) (Stage 1))	N/A	(100%)	(86.2%)	63,926	(0.011)

304

305 Table 2: An overview of previously conducted genome-wide association studies for depression and
306 Alzheimer's disease used in this study. Heritability estimates were calculated naively on the liability
307 scale from these standardised summary statistics using Linkage Disequilibrium Score Regression
308 (LDSC), taking a population prevalence of 15% for depression and 5% for Alzheimer's disease.

309

310

2.2.1 Clinical and broad depression

To examine potential differences in genetic overlap with AD between depression as 311 a disorder compared to individual depression symptoms, summary statistics for two 312 313 previously conducted GWAS of clinical and broad depression were obtained from Consortium 314 the Psychiatric Genomics (PGC) (https://pqc.unc.edu/for-315 researchers/download-results/). For clinical depression, we used a subsample of the 316 Major Depressive Disorder (MDD) GWAS by Wray et al.¹¹ that excluded samples from the UKB and 23andMe, and contained only individuals for whom case ascertainment 317 was defined through structured diagnostic interview or electronic health records. For 318 the broad definition depression GWAS, we used a subsample of the depression 319 GWAS by Howard et al.¹², which also excluded samples from 23andMe. In addition 320

to clinical cases and controls used by Wray et al.¹¹, this broad depression GWAS 321 included individuals in the UKB for whom case-control ascertainment was based on 322 self-reported responses to the questions "Have you ever seen a general practitioner 323 324 for nerves, anxiety tension or depression?" and "Have you ever seen a psychiatrist 325 for nerves anxiety, tension or depression?".

326

2.2.2 Alzheimer's disease

Summary statistics were obtained from six previously conducted AD GWAS: three 327 with proxy+clinical, one with proxy-only and two with clinical-only case 328 329 ascertainment. All three of the proxy+clinical AD GWAS - Bellenguez et al.¹⁷, Wightman et al.¹⁶ and Jansen et al.¹⁵ – and the proxy-only AD GWAS – Marioni et al.³⁷ 330 - used data from the UKB for proxy AD samples. 331

There are some key differences in the way these AD GWAS define proxy cases 332 and controls. Bellenguez et al.¹⁷ define proxy cases/controls as a binary phenotype, 333 334 whereby individuals reporting a parent with AD or dementia are considered cases and those reporting no parental history are considered controls. Wightman et al.¹⁶ 335 and Jansen et al.¹⁵ instead define proxy cases/control as a continuous phenotype, 336 337 summing the number of parents an individual has reported with dementia and downweighting unaffected parents by their age (or age of death). 338

For the proxy-only Marioni et al.³⁷ GWAS, summary statistics were obtained 339 from a meta-analysis of paternal and maternal AD. Here, proxy phenotyping was 340 based on the self-report of either maternal or paternal AD, including the parent's age 341 342 at time of reporting/age of death as a covariate.

Summary statistics from a clinical-only subsample of the GWAS by Wightman 343 344 et al. that excluded proxy cases/controls from the UKB⁴⁵ were obtained from the authors. Summary statistics for a final clinical-only AD GWAS were obtained from 345 Stage 1 of the GWAS by Kunkle et al.¹⁴. 346

347

2.3 Summary statistic standardisation

Summary statistics from all 40 depression symptom GWAS, the two depression 348 GWAS and the six AD GWAS, were standardised using the MungeSumstats⁵⁵ in R 349 version 4.2.1. Using dbSNP 141 and the BSgenome. Hsapiens. 1000genomes. hs37d5 350 reference genome, missing rsIDs were corrected, duplicates and multi-allelic variants 351 removed, effect alleles and the direction of their effects aligned to the reference 352 genome, and variants filtered at INFO score \geq 0.7 and MAF \geq 0.01. The GLAD Study 353 and Bellenguez et al.¹⁷ summary statistics were lifted over from GRCh38 to GRCh37. 354

2.4 SNP heritability 355

SNP heritability (h^2_{SNP}) estimates were calculated for all GWAS used in this 356 study with Linkage Disequilibrium Score Regression (LDSC)^{56,57}. Briefly, LDSC 357 calculates h^2_{SNP} by regressing the effect sizes from GWAS summary statistics on their 358

LD score as computed in a reference panel – in this case HapMap3 variants contained within the European sample of 1000 Genomes Phase 3. Liability scale h^2_{SNP} was calculated naively from the standardised depression GWAS and AD GWAS using a 15% and 5% population prevalence respectively^{11,16}. Heritability *Z*-scores were calculated for all phenotypes by dividing the h^2_{SNP} estimates by their standard error.

364

2.5 GWAS meta-analysis of depression symptoms

To leverage the maximum genetic information available controlling for the 365 sample overlap between the UKB-MHQ and UKB-EoP samples, REGENIE output for 366 each PHQ-9 phenotype from the UKB-EoP, GLAD Study and PROTECT were first 367 subject to Inverse Variance Weighted (IVW) meta-analysis using METAL⁵⁸. All 368 available variants were included, for a total of 8,425,618 (N = 175,692). Multi-trait 369 Analysis of GWAS (MTAG)⁵⁹ v1.0.8 was then used to meta-analyse the METAL output 370 with the UKB-MHQ sample. While MTAG is commonly used for the joint genetic 371 372 analysis of multiple traits or multiple measurements of the same trait, by assuming the 373 heritability of included phenotypes are equal (--equal-h2) and their genetic correlation is one (--perfect-gencov), MTAG performs an IVW meta-analysis of the same 374 measures of the same trait, accounting for sample overlap using the cross-trait 375 intercept from LDSC^{56,57}. Heritability estimates for all samples, plus the METAL meta-376 377 analysis, are in **Supplementary Table 2**. Genetic correlations between the UKB-MHQ and METAL GWAS are in Supplementary Table 3. For greater detail on the IVW 378 379 function of MTAG, see the online methods of the original MTAG paper⁵⁹. A total of 8,196,874 SNPs with MAF > 0.01 were present for MTAG analysis. 380

This MTAG function provides one set of summary statistics and two GWASequivalent sample sizes – one for each original sample included. A single, weighted GWAS-equivalent *N* was obtained for each PHQ-9-MTAG GWAS, using the following formula;

385

386

$$N(final) = \frac{(N_1(pre)*N_1(post)) + (N_2(pre)*N_2(post))}{N_1(pre) + N_2(pre)}$$

387

where N_1 and N_2 represents the UKB-MHQ and METAL GWAS respectively, *pre* is the mean sample size prior to inclusion in MTAG and *post* is the GWASequivalent sample estimated by MTAG following analysis.

391

2.6 Genomic risk loci and gene annotation

392GWAS meta-analysis results were annotated using FUMA GWAS⁶⁰ v3.1.6a. Genome-393wide significance was set at $p \le 5e$ -8. Lead variants at genomic risk loci were defined394by clumping all variants correlated at $r^2 > 0.1$ 250kb either side. Clumping was395performed using the European sample of the 1000 Genomes Phase 3 reference

panel. Lead variants were mapped to genes within 10kb using positional mapping
and eQTLs from four brain (BrainSeq⁶¹, PsychENCODE⁶², CommonMind⁶³, and
BRAINEAC⁶⁴) and five blood (BloodeQTL⁶⁵, BIOS⁶⁶, eQTLGen cis and trans⁶⁷, Twins
UK⁶⁸ and xQTLServer⁶⁹) eQTL datasets, alongside all 54 tissue type eQTLs from GTEx
v8 (https://gtexportal.org/home/tissueSummaryPage).

401

2.7 Genetic correlations

402 Genetic correlation can be understood as the genome-wide correlation of genetic
403 effects between two phenotypes, and as such can be viewed as an estimate of
404 pleiotropy⁷⁰.

405 Genetic correlations were calculated between each depression phenotype and the six AD GWAS using High Definition Likelihood v1.4.1 (HDL)⁷¹. HDL extends 406 the LDSC framework by leveraging LD information from across the whole LD 407 reference panel through eigen decomposition, thus shrinking standard errors and 408 409 improving precision. A pre-computed eigenvector/value LD reference panel 410 calculated from 335,265 individuals of European ancestry in the UKB was obtained via the HDL GitHub (https://github.com/zhenin/HDL/wiki/Reference-panels). This 411 reference panel was calculated using 1,029,876, imputed, autosomal HapMap3 412 SNPs, with bi-allelic SNPs outside the MHC region, MAF > 5%, a call rate > 95% and 413 414 INFO > 0.9 retained.

415

2.8 Local genetic correlations

416 Local genetic correlation assesses the correlation of genetic effects between two
417 phenotypes in specific region of the genome. It provides a more refined examination
418 of the genetic overlap between two phenotypes, allowing for the identification of key
419 regions driving shared genetic architecture.

LAVA⁷² was used to assess regions of local genetic correlation between each 420 depression phenotype and the six AD GWAS across 2495 semi-independent, pre-421 422 defined LD-blocks of at least 2500 base pairs (https://github.com/josefin-423 werme/LAVA). Loci-specific heritability estimates were calculated for each phenotype for each block. If both a depression phenotype and an AD GWAS showed 424 425 significant local heritability at a specific locus (Bonferroni corrected *p*-value \leq 2e-5 (0.05/2495)), bivariate local genetic correlation was tested. Bivariate results were 426 considered significant at $p_{\text{FDR}} \leq 0.05$ correcting for the total number of bivariate tests. 427 428 Sample overlap was accounted for using an LDSC intercept matrix. Analysis was 429 restricted to the 5,531,969 non-strand-ambiguous variants shared across all GWAS 430 summary statistics and on the European ancestry 1000 Genomes Phase 3 reference 431 panel.

- 432
- 433

434 **2.9 Colocalisation**

435 Colocalisation using COLOC is a Bayesian statistical method to assess the
436 probability of two phenotypes sharing a causal variant in a pre-defined genomic
437 region.

Within the colocalisation framework, posterior probability is assessed for fivehypotheses:

440

441 H₀: There is no causal variant in the region for either phenotype

442 H_1 : There is a causal variant in the region for the first phenotype

443 H_2 : There is a causal variant in the region for the second phenotype

444 H₃: Distinct causal variants for each trait in the region

445 H₄: Both traits share a causal variant.

446

447 Colocalisation analysis was conducted using the COLOC-reporter pipeline⁷³ 448 (https://github.com/ThomasPSpargo/COLOC-reporter). COLOC-reporter extracts variants in user-defined genomic regions and calculates the LD matrix for this region 449 from a user-defined reference panel. It then harmonises the summary statistics to 450 451 match the allele order of the reference panel, flipping effect directions accordingly. 452 Observed versus expected Z-scores are assessed using the diagnostic tools provided in the susieR R package⁷⁴. Z-score outliers are omitted. Following this QC, 453 Sum of Single Effects (SuSiE) fine-mapping⁷⁴ is conducted to identify 95% credible 454 sets in these regions for each phenotype. Identification of credible sets in both 455 456 phenotype allows for the relaxation of the single causal variant assumption. All 457 possible credible sets are then assessed pairwise for shared signal between phenotypes, improving resolution for colocalisation inference in regions containing 458 multiple signals⁷⁵. Should no 95% credible set be identified or only identified for one 459 phenotype, colocalisation under the single causal variant assumption is performed 460 using the *coloc.abl*⁷⁶. A posterior probability \geq 80% for H₄ was considered evidence 461 of colocalisation between two phenotypes (PP.H₄ \ge 0.8). The SuSiE model assumed 462 at most 10 causal variants (L = 10) per credible set. We used default priors. 463

Trait pairs with LAVA correlations significant at $p_{\text{FDR}} \leq 0.05$ were passed to COLOC-reporter. Where the same depression phenotype showed nominally significant local genetic correlation at the same locus but with different AD GWAS, these phenotype pairs were included as a sensitivity analysis. Regions +/-250kb (r² ≥ 0.1) from lead variants at genome-wide significant loci from the MTAG-PHQ-9, broad and clinical depression GWAS were also examined for evidence of colocalisation with the 6 AD GWAS.

472 **2.10 Mendelian randomisation (MR)**

473 MR is a statistical method that uses genetic variants associated with an exposure as 474 instrumental variables to assess the causal effect of that exposure on an outcome of 475 interest⁷⁷. Two Sample MR framework estimates the causal relationships between an exposure and outcome using GWAS summary statistics. Valid MR instruments are 476 defined by three key assumptions: (1) relevance – IVs are strongly associated with 477 the exposure of interest; (2) independence - there are no confounders in the 478 association between IVs and the outcome of interest; and (3) exclusion restriction -479 480 instruments are not associated to the outcome other than via the exposure, for 481 example through horizontal pleiotropy⁷⁷.

Sample overlap is a known source of bias in Two Sample MR⁷⁸. Given the
likelihood of sample overlap between the depression phenotypes and the AD GWAS
containing proxy cases/controls due to participants from the UKB, MR analysis was
primarily conducted using Causal Analysis Using Summary Effect estimates
(CAUSE)⁷⁹ v1.2.0. CAUSE is a Bayesian MR method robust to sample overlap,
correlated and uncorrelated pleiotropy, also avoiding exclusion restriction
assumption violations⁸⁰.

In CAUSE, the presence of a significant causal effect, γ , is derived by comparing the expected log pointwise posterior density (ELPD) of a sharing model with γ fixed to zero to a causal model where γ is a free parameter for a one-tailed pvalue test. The posterior median of γ describes the causal effect estimate and is reported alongside its 95% credible intervals. CAUSE uses a larger set of instruments that traditional MR methods. As such, clumping was performed with the default setting at r² ≥ 0.01 and a *p*-value ≤ 0.001 within a 10,000kb window.

Causal estimates were also calculated using the traditional IVW method. IVW
estimates are biased by the presence of horizontal pleiotropy⁸¹. Sensitivity analyses
were therefore conducted using MR-Egger, weighted-median and weighted-mode
MR. These methods allow for varying degrees of pleiotropy while providing unbiased
causal estimates⁸²⁻⁸⁴. MR-PRESSO⁸⁵ was also implemented. MR-PRESSO identifies
and excludes outlying instruments based on their contribution to heterogeneity and
provides a corrected causal estimate.

Pleiotropy was assessed using the MR-Egger intercept test⁸⁶ (significant pleiotropy: *p* ≤ 0.05). Heterogeneity tests were also conducted for IVW and MR-Egger estimates using their respective Cochran's Q test⁸⁷ (significant heterogeneity: *p*-value ≤ 0.05). Instrument strength was calculated via the minimum and mean F-statistic (recommended F-statistic ≥ 10)⁸⁸ (β²/SE²). I² was calculated to ensure measurement error was sufficiently low so as to ensure validity of results from MR-Egger (recommended I² ≥ 0.90)⁸⁹.

510 For IVW-MR, MR-Egger, weighted-median and weighted-mode MR, 511 instruments clumped at a $r^2 \ge 0.001$ and a *p*-value $\le 5e-8$ within 10,000kb. Where no 512 instruments were available at $p \le 5e-8$ or where < 5 instruments were available, a *p* 513 $\le 5e-6$ threshold was used.

514 For all analyses, instruments were clumped using data from individuals of 515 European ancestry in 1000 Genomes Phase 3. IVW, MR-Egger, weighted-median and 516 weighted-mode analyses were conducted using the TwoSampleMR package v0.5.6.

The *APOE* gene is known to be associated with non-AD phenotypes such as cardiovascular disease⁹⁰ and type 2 diabetes $(T2D)^{91}$. Both have been linked to depression in previous MR analyses^{92,93}. As such, the inclusion of *APOE* would violate MR's independence assumption. All MR analyses were therefore conducted excluding variants in the APOE region (chr19:45,020,859–45,844,508 (GRCh37)) as per Lord et al.⁹⁴.

523

2.11 Polygenic risk scores (PRS)

524 Polygenic risk scores (PRS) describe the sum of an individual's risk alleles, weighted by their effect size⁹⁵. The ten PHQ-9-MTAG, clinical depression and broad definition 525 depression GWAS were processed for PRS using the BayesR-SS function contained 526 within MegaPRS and implemented in LDAK v5.2.1.96. BayesR-SS assumes the BLD-527 528 LDAK heritability model, which incorporates 65 genome annotations pertaining to 529 genomic features such as whether the variants are in coding regions or highly 530 conserved⁹⁶. Annotation files were obtained from the LDAK website (http://dougspeed.com/bldldak/). PRS calculation was restricted to the 1,217,311 531 532 HapMap3 SNPs, with strand ambiguous SNPs excluded.

PRS predictive utility for AD case/control status was assessed using logistic regression in three clinically ascertained AD cohorts: AddNeuroMed and Dementia Case Register Studies (ANM)⁹⁷ ($N_{cases} = 564$; $N_{controls} = 345$), the Alzheimer's Disease Neuroimaging Initiative (ADNI) (<u>https://adni.loni.usc.edu</u>) ($N_{cases} = 356$; $N_{controls} = 360$), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD1) Consortium

539 (https://portal.dementiasplatform.uk/CohortDirectory/Item?fingerPrintID=GERAD)

540 ($N_{cases} = 2,661$; $N_{controls} = 1,124$) (Supplementary Table 4). All analyses controlled for 541 age, sex, and 10 PCs, and were restricted to individuals aged ≥ 65 to provide clean 542 controls. As a sensitivity analysis, PRS were also calculated in these cohorts 543 excluding the *APOE* region. Genetic QC and imputation steps for these cohorts can 544 be viewed in detail in the study by Lord et al.⁹⁸.

- 545
- 546
- 547

548 3. RESULTS

549 3.1 PHQ-9 genome-wide meta-analyses

550 The MTAG meta-analyses identified a total of 40 genomic risk loci between the ten PHQ-9 phenotypes (GWAS equivalent N range: 224,535 - 308,421). Only one 551 depression symptom - suicidal thoughts - identified no genome-wide significant 552 variants. Three lead SNPs were shared with more than one PHQ-9 phenotype, leaving 553 a total of 37 unique genomic risk loci (Table 3). The significance of each of the lead 554 variants in each of the samples contributing to the meta-analysis can be seen in 555 Supplementary Table 5. eQTL mapping in FUMA mapped lead variants at genomic 556 risk loci to 76 genes (Supplementary Table 6). h_{SNP}^2 for the MTAG-PHQ-9 GWAS 557 ranged from 1.12% for suicidal thoughts to 6.78% for the PHQ-9 sum-score. h²_{SNP} Z-558 scores were all > 4 (range: 6.59 - 18.50) (Supplementary Table 7), indicating 559 560 sufficient heritability to obtain reliable genetic correlation estimates in downstream 561 analyses⁵⁷. Genomic inflation factors (λ_{GC}) ranged from 1.0638 to 1.2156, with LDSC intercepts ranging from 0.9997 to 1.0007, indicating inflation was due to polygenic 562 signal as opposed to confounding due to population stratification^{56,99}. Manhattan and 563 QQ plots can be viewed in Figure 2. 564

569

570 571

								= ((
Genomic Locus	CHR	Position	Lead Variant	Phenotype	p-value	BETA	SE	Effect Allele	MAF	Nearest Gene	eQTL Genes	
1	1	21059837	rs61778528	Anhedonia	1.27E-08	-0.011	0.002	Т	0.384	RP5-930J4.2	KIF17, SH2D5, ECE1, HP1BP3, EIF4G3	
2	1	51661974	rs36116328	Concentration Problems	2.94E-08	0.011	0.002	С	0.052	RP11-296A18.3	EPS15, TTC39A, RNF11, CDKN2C,	
3	1	201787833	rs2494112	Sleep Problems	4.46E-08	0.011	0.002	Α	0.486	NAV1:IPO9-AS1	NAV1, LMOD1, SHISA4, RNPEP,	
4	1	201859213	rs61824384	Fatigue PHQ-9 Sum Score	3.81E-09 4.48E-11	-0.012 -0.014	0.002	G	0.385	SHISA4 SHISA4	NAV1, LMOD1, SHISA4, IPO9, TIMM17A, RNPEP	
5	1	201919674	rs2790898	Feelings of Inadequacy	4.48E-11 2.54E-08	0.014	0.002	T	0.385	LMOD1	LMOD1 , RNPEP, IPO9, SHISA4, TIMM17A	
6	2	66750564	rs113851554	Sleep Problems	1.42E-14	0.011	0.002	Т	0.423	MEIS1	MEIS1	
7	3	48812594	rs116113836	Depressed Mood	2.74E-08	0.011	0.002	A	0.033	PRKAR2A	AMT, ZNF589, ATRIP, NME6, WDR6, P4HTM, QRICH1, NICN1, RNF123, GMPPB, LAMB2, USP4, MST1, TREX1, TMA7, KLHDC8B	
8	3	117535095	rs76917635	Feelings of Inadequacy	1.65E-08	-0.012	0.002	G	0.194	SAMP:RP11-384F7.	-	
9	3	117822025	rs7619072	Sleep Problems	7.14E-11	0.013	0.002	C	0.229	RP11-384F7.1	LSAMP	
10	4	106217349	rs2647239	Sleep Problems	1.17E-08	-0.012	0.002	G	0.420	RN7SL89P	PPA2, TET2	
11	5	62392481	rs181208594	Psychomotor Changes	2.72E-08	0.011	0.002	G	0.017	RP11-586E1.1	-	
12	6	28548674	rs146918648	Appetite Changes	1.49E-08	0.012	0.002	А	0.027	SCAND3	ZSCAN9, PGBD1, ZKSCAN3, ZNF165, TRIM27, ZSCAN23, SCAND3, ZSCAN12, C6orf100"	
13	6	32555944	rs35773267	Fatigue	1.63E-09	0.013	0.002	Т	0.372	HLA-DRB1	-	
14	7	12250378	rs3807866	Depressed Mood	4.38E-08	0.011	0.002	Α	0.398	TMEM106B	TMEM106B	
15	7	12277442	rs13234970	Appetite Changes	1.56E-08	0.012	0.002	C	0.400	TMEM106B	-	
16	7	12285140	rs12699338	PHQ-9 Sum Score	8.47E-09	0.012	0.002	Т	0.405	TMEM106B	TMEM106B	
17	7	82394712	rs763296	Fatigue	1.03E-10	0.013	0.002	G	0.495	PCLO	-	
18	7	121955328	rs3958046	Appetite Changes	3.58E-09	0.012	0.002	Т	0.389	CADPS2	-	
19	8	19551329	rs13253689	Fatigue	4.55E-08	-0.011	0.002	С	0.243	CSGALNACT1	INTS10, CSGALNACT1, LPL	
20	8	37211598	rs150773120	Appetite Changes	1.19E-08	0.012	0.002	Α	0.012	RP11-527N22.1	-	
21	8	73452488	rs7824350	Fatigue	8.58E-09	-0.012	0.002	G	0.410	KCNB2	-	
22	10	11149133	rs61830447	Inadequacy	3.80E-08	0.011	0.002	Α	0.243	CELF2	CELF2	
23	12	57323523	rs840161	PHQ-9 Sum Score	3.71E-09	0.012	0.002	G	0.339	SDR9C7	METTL21B, TMEM194A, STAT6, NAB2, RBMS2, LRP1	
24	12	57331741	rs725957	Fatigue	4.68E-08	0.011	0.002	А	0.394	SDR9C7	METTL21B, TMEM194A, STAT6, NAB2, RBMS2, LRP1, RDH16, DTX3, SDR9C7	
25	12	109874794	rs10850137	Fatigue	1.11E-09	0.013	0.002	G	0.336	MYO1H	UBE3B, MMAB, ACACB, KCTD10, MVK, MYO1H FOXN4, UNG	
				Depressed Mood	2.81E-08	0.011	0.002	G	0.103	MIR4704		
26	13	66718798	rs185907577	Fatigue	4.11E-09	0.012	0.002	G	0.103	MIR4704	-	
				PHQ-9 Sum Score	9.73E-10	0.013	0.002	G	0.103	MIR4704		
27	16	53801549	rs9923147	Appetite Changes	1.74E-11	0.014	0.002	Т	0.443	FTO	FTO	
28	17	56044110	rs11654634	PHQ-9 Sum Score	8.48E-10	0.013	0.002	С	0.067	VEZF1	CUEDC1, TEX14	
29	17	56124979	rs11657437	Anhedonia	2.62E-08	0.011	0.002	Α	0.105	RP11-159D12.10	VEZF1	
30	17	65989971	rs113985803	Appetite Changes	4.18E-08	-0.011	0.002	Α	0.226	RP11-855A2.5	BPTF, KPNA2, PSMD12	
31	17	66045831	rs74354868	Fatigue	2.78E-08	0.011	0.002	Α	0.229	KPNA2	BPTF, KPNA2, C17orf58, ARSG, PSMD12	
32	18	35127427	rs1557341	PHQ-9 Sum Score	1.94E-08	-0.012	0.002	С	0.341	CELF4	-	
33	18	50754093	rs62100775	Fatigue PHQ-9 Sum Score	1.92E-08 1.44E-08	0.012	0.002	G G	0.419	DCC DCC	DCC	
34	18	50829023	rs11877505	Anhedonia	3.40E-09	0.012	0.002	G	0.388	DCC	DCC	
35	18	53415377	rs4800995	Fatigue	4.60E-10	0.013	0.002	A	0.214	RP11-397A16.1	-	
36	18	71620555	rs75020204	Sleep Problems	4.34E-08	-0.011	0.002	C	0.071	RP11-25L3.3	_	
37	19	7871720	rs3223231	Anhedonia	4.40E-09	-0.012	0.002	A	0.462	EXOSC3P2	_	
573											1	

574

575 Table 3: Genomic risk loci from the 10 MTAG-PHQ-9 genome-wide association meta-analyses. Nearest gene is

576 based on positional mapping and ANNOVAR annotation. Expression quantitative trait loci (eQTL) mapping was

577 *limited to* $p_{FDR} \le 0.05$ *in the selected eQTL datasets (see: Methods). Specific tissues with significant* p_{FDR} *can be*

578 seen in Supplementary Table 2.




Figure 2: Manhattan and QQ-plots for each of the 10 MTAG-PHQ-9 GWAS meta-analyses. The red lines on the Manhattan plots indicate genome-wide significance ($p \le 5 \times 10^8$), while the blue lines indicates suggestive significance ($p \le 1e-5$). Top variants at each genomic risk loci are annotated.

583

584 585

3.2 Genetic correlations

Of the 72 bivariate genetic correlations calculated between the 12 depression 586 phenotypes and the six AD GWAS, 24 were nominally significant and 20 remained 587 588 significant at $p_{\text{FDR}} \le 0.05$ (r_q range: -0.25 – 0.35; p-value range: 1.25 x 10⁻² – 4.01 x 10⁻² ⁵; p_{FDR} range: 4.5 x 10⁻² – 1.9 x 10⁻³). Of these, 19 were identified when the AD GWAS 589 590 in the pair contained either clinical+proxy cases and controls, or proxy-only cases 591 and controls (Figure 3; Supplementary Table 8). Only one p_{FDR} significant association was found when using a clinical AD GWAS - between suicidal thoughts and 592 Wightman et al. ($r_q = -0.25$, p = 6.78 x 10⁻³, p-value = 6.78 x 10⁻³; $p_{EDR} = 3.48 \times 10^{-2}$). 593 All depression phenotypes were significantly genetically correlated with each other 594 595 $(r_{a} \text{ range: } 0.57-0.98; p \text{-values } \le 3.71 \times 10^{-23})$ (Supplementary Table 9). Only one PHQ-9 symptom pair – concentration problems and psychomotor changes – showed 596 a genetic correlation that was not statistically different from one (95% CI included 597 598 one), indicating genetic heterogeneity across depression symptoms.

- 599
- 600 601
- 001
- 602

603

- 604
- 605



607

608Figure 3: Heatmap of High Definition Likelihood (HDL) calculated genetic correlations between609depression items and the six Alzheimer's disease genome-wide association studies of varying610proxy/clinical case/control ascertainment. The colour of each square indicates the strength of the611correlation on a scale of -1 to 1. Fill size of the square indicates uncorrected p-value significance.612Genetic correlations significant at $p_{FDR} \leq 0.05$ are circled.

- 613
- 614

615

3.3 Local genetic correlations

After univariate testing, a total of 4271 bivariate local genetic correlation tests were 616 conducted across 324 genomic loci. Of these tests, 716 were nominally significant 617 and 15 remained significant at $p_{FDR} \leq 0.05$ across 14 unique genomic loci (local r_q 618 range: -0.81 - 0.82; *p*-value range: $1.48 \times 10^{-4} - 4.2 \times 10^{-6}$; *p*_{FDR} range = $4.22 \times 10^{-2} - 4.2 \times 10^{-2}$ 619 1.38 x 10⁻²) (Supplementary Table 10). Of the 15 statistically significant tests, ten were 620 identified when using clinical+proxy/proxy-only AD GWAS. No depression phenotype 621 showed a statistically significant association at the same genomic locus with more 622 than one AD GWAS. However, for ten of the 15 statistically significant tests, nominally 623 624 significant local genetic correlation was observed between the depression phenotype and at least one additional AD GWAS at the same loci (Supplementary 625 **Table 11**). Only locus 1790 (chr12:51769420– 53039987) showed p_{FDR} significant 626 local genetic correlation with more than one depression phenotype – concentration 627 problems and sleep problems, both with the clinical-only Wightman et al. GWAS. The 628 629 number of positively and negatively correlated loci identified between each phenotype pair can be viewed in Supplementary Table 12. 630

631

632 3.4 Colocalisation

633 Following LAVA. 14 p_{FDR} significant regions of local genetic correlation were passed to the COLOC-reporter pipeline across 15 depression-AD phenotype pairs. A further 634 14 colocalisation tests were conducted where nominally significant local genetic 635 636 correlation was observed at a p_{FDR} significant loci between the same depression phenotype and a different AD GWAS. As such, a total of 29 statistical colocalisation 637 638 tests were conducted to follow up LAVA results. No 95% credible sets were identified 639 by SuSiE for any phenotype pairs in these regions. As such, all analyses were conducted under the single causal variant assumption of *coloc.abf*. There was no 640 641 evidence of colocalisation in any of these loci (mean PP.H₄ = 0.59%) (Supplementary Table 11). All but two of these tests indicated no causal variant present in either 642 643 phenotype (PP.H₀ > 0.8). The two tests in locus 319 (chr2:126754028-127895644), indicated strong probability of a causal variant for the Kunkle et al.¹⁴ and Wightman 644 et al.⁴⁵ clinical AD GWAS (PP.H₂ > 0.9) . This locus contains *BIN1*, a known risk gene 645 for AD involved in tau regulation^{100,101}. 646

An additional 762 colocalisation tests were conducted with the six AD GWAS 647 648 using regions +/-250kb ($r^2 > 0.1$) lead variants from the MTAG-PHQ-9, broad and 649 clinical depression GWAS. SuSiE identified evidence of colocalisation in regions +/-650 250kb of lead variants at genomic risk loci 14 (depressed mood), 15 (appetite change), 16 (PHQ-9 sum score) and for broad depression at chr7:12000402-651 12500402 (PP.H₄ range: 0.79 – 0.85), all with the same three AD GWAS – Bellenguez 652 653 et al.¹⁷, Wightman et al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ (Supplementary
 Table 13). These colocalisations were all in the region of the transmembrane protein
 654 106B gene (TMEM106B) – visualised using LocusZoom¹⁰² in Figure 4. Colocalisation 655 was also identified for the same phenotype pairs at the same loci under the single 656 causal variant assumption of *coloc.abf* (Supplementary Table 14). The same 657 depression phenotypes and loci were suggestive of colocalisation with Jansen et al.¹⁵ 658 (PP.H₄ > 0.6). In a follow-up analysis, we assessed statistical colocalisation +/-250kb 659 660 TMEM106B (chr7:12000920-12532993) between these four AD GWAS and all remaining depression phenotypes. Additional evidence of colocalisation was 661 identified at TMEM106B between fatigue and the Bellenguez et al.¹⁷, Wightman et 662 al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ AD GWAS (Supplementary Table 15), 663 and was suggestive for Jansen et al.¹⁵ (Supplementary Table 16). Evidence of 664 colocalisation was also suggestive for psychomotor changes with Bellenguez et al.¹⁷, 665 Wightman et al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ (PP.H₄ > 0.6). 666

667 668




Figure 4: LocusZoom plots of the transmembrane protein 106B (TMEM106B) gene region containing
evidence of colocalisation (PP.H₄ ≤ 0.8). for (A.) broad depression, (B.) appetite changes, (C.)
depressed mood, (D.), the PHQ-9 sum score, (E.) Bellenguez et al., (F.) Wightman et al. and (G.)
Wightman et al. excluding the UK Biobank. The most significant variant for each phenotype is labelled
in their respective plot.

676

677 **3.5 Mendelian Randomisation**

We conducted 144 MR tests between the depression phenotypes and AD – 72 in
each direction. In CAUSE, no significant causal association was identified between
any of the depression items and AD in either direction even at nominal significance
(Supplementary Table 17).

F-statistics indicated that instrument strength was sufficient (F_{Mean} range: 22.43 682 - 63.36; F_{Min} range: 20.84 - 31.56; F_{Max} range: 26.37 - 402.86), as did I² for instrument 683 suitability for MR-Egger (I² range: 0.91 – 0.98). A $p_{\text{FDR}} \leq 0.05$ was applied in each of 684 the other MR methods to correct for the 144 tests conducted, after which no 685 statistically significant associations were observed in any method. Three nominally 686 significant causal associations where a depression item was the exposure (β range 687 = 0.21 - 1.59; *p*-value range = 0.01 - 2e-3) and two where an AD GWAS was the 688 exposure (β range = 0.018 - 0.02; p-value range = 0.01 - 0.02) were detected by 689

IVW-MR, of which three we nominally significant in weighted-median MR. No 690 significant pleiotropy (MR-Egger intercept test p-value ≤ 0.05) or heterogeneity (IVW) 691 Cochran's Q p-value \leq 0.05) was detected for these five tests. However, nominally 692 693 significant estimates were only observed between exposures and outcomes where the AD GWAS contained proxy+clinical or proxy-only cases/controls and where the 694 695 GWAS used for both exposure and outcome were either majority or entirety derived from the UK Biobank, suggesting sample overlap as a potential source of bias. MR-696 PRESSO detected and excluded significant outliers in 42 tests, returning outlier-697 698 corrected causal estimates. Results remained non-significant. Full MR results can be viewed in Supplementary Table 18. 699

700

3.6 Polygenic risk scores (PRS)

No statistically significant associations were detected between any of the depression phenotype PRS and AD case/control status in any of the three AD target samples $(p_{\text{FDR}} \le 0.05, \text{ corrected within each sample}), with only the suicidal thoughts PRS$ negatively nominally associated with AD case/control in the ADNI cohort $(Nagelkerke's pseudo-r2 = 0.01, OR [95% CI] = 0.83 [0.72–0.94], <math>\beta$ = -0.19, SE = 0.07, *p*-value = 7.90 x 10⁻³). Exclusion of the APOE region had no effect on results (Supplementary Table 19).

708 709

4. Discussion

In this study, we performed the first and largest genome-wide meta-analysis of PHQ-710 711 9 depression symptom items to date (GWAS equivalent Nrange: 224,535 – 308,421), 712 identifying 37 genomic risk loci. Follow-up analyses examining the genetic overlap 713 between depression/depression symptoms and AD identified 20 significant global 714 correlations and 15 significant local correlations at 14 loci across six AD GWAS with varying proportion of clinical case/control ascertainment. Significant global genetic 715 correlation were primarily with AD GWAS containing proxy cases and controls. No 716 colocalisation was identified at any of the regions of local genetic correlation. 717 718 However, there was strong evidence of colocalisation between depression several phenotypes and AD in the region of *TMEM106B*. Overall, MR did not suggest that 719 720 depression or its symptoms were causal for AD, nor vice versa, while polygenic risk 721 scores for depression phenotypes were not predictive of AD case/control status in 722 three clinical AD samples.

The increased power of our PHQ-9 GWAS allowed for the identification of 28 more genomic risk loci than the previous analysis by Thorp et al.²⁹. Several of the loci identified in this study have shown previous associations with related phenotypes. For example, *SHISA4* – here identified in association with fatigue symptoms – has been previously implicated as playing a role in disrupted sleep¹⁰³ and daytime

napping¹⁰⁴. The top variant for sleep problems at genomic risk loci 6 (MEIS1) -728 729 rs113851554 (chr2: 66750564) - was also the top variant in a previous GWAS of insomnia and restless leg syndrome¹⁰⁵. Additionally, the obesity gene *FTO*¹⁰⁶ was 730 731 identified as a genomic risk loci for appetite changes. Although the role of FTO in depression is inconclusive¹⁰⁷, it has been recently linked to anxiety and depression 732 symptoms in individuals with anorexia nervosa (AN)¹⁰⁸. Consequently, its 733 identification in association with appetite change symptoms – a phenotype relevant 734 to eating behaviours - suggests that symptom-based genetic analysis can help 735 736 identify the phenotype-relevant biology of individual depression symptoms. Taken alongside the fact that only three of the genomic risk loci were shared between more 737 than one depression symptom phenotype, our GWAS meta-analysis backs findings 738 by Thorp et al.²⁹ of genetic heterogeneity between depression symptoms. 739

Our findings also highlight genetic similarities between depression symptoms. 740 741 For example, *TMEM106B* – a gene identified in previous depression GWAS^{11,12} – was the nearest gene to lead variants for three PHQ-9 items - appetite changes 742 (rs13234970), depressed mood (rs3807866) and the PHQ-9 sum score 743 (rs12699338). TMEM106B was strongly suggested as a causal gene in a recent multi-744 ancestry depression GWAS¹⁰⁹. Further, dysregulation of *TMEM106B* expression has 745 been implicated in association with MDD¹¹⁰ and with anxious and weight gain MDD 746 subtypes – both associated with treatment resistance¹¹¹. *TMEM106B* has also been 747 implicated in self-reported diagnosis of anxiety disorder¹¹², neuroticism¹¹³ and in a 748 latent factor GWAS of depressive, manic and psychotic symptoms/disorders¹¹⁴, 749 suggesting it is linked to psychiatric risk more generally. 750

751 That colocalisation is observed in the *TMEM106B* region between multiple depression phenotypes and both proxy+clinical and clinical-only AD is therefore of 752 particular interest. TMEM106B plays a role in lysosomal function - particularly in 753 754 motor neurons¹¹⁵ – and is classically considered a risk gene for frontotemporal dementia¹¹⁶. It is has also been identified in recent AD GWAS^{16,17}, and is associated 755 756 with brain aging, cognitive decline, and neurodegeneration across other brain 757 disorders including Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's 758 Disease¹¹⁷⁻¹²². Further, TMEM106B has been linked to higher CSF levels of neurofilament light (NfL)¹²³ – itself predictive of cognitive decline, brain atrophy and 759 cortical amyloid burden in individuals with AD and Mild Cognitive Impairment 760 761 (MCI)¹²⁴. A recent study also identified higher levels of plasma NfL in individuals with depression, although the sample size of this study was relatively small¹²⁵. Thus, 762 colocalisation between depression phenotypes and AD at *TMEM106B* indicates that 763 depression may itself be genetically linked to overall brain health and resulting 764 general dementia risk. Two previous studies have identified *TMEM106B* as playing a 765 role in both depression and AD^{20,21}. However, our study suggests that this overlap 766

767 may be driven by the genetic architecture of specific depression symptoms,768 highlighting the benefits of symptom-level genetic analysis.

769 A mixed picture is painted across our other downstream analyses. 770 Depression/depression symptom PRS were not predictive of AD case/control status 771 in three clinical samples. Additionally, we do not find evidence of any causal associations using MR. These MR findings are in line with a number of previous 772 studies^{19,39}, but in contradiction to that conducted by Harerimana et al.²². In this study, 773 774 we do not recapitulate the causal association identified by Harerimana et al.²² for 775 broad depression on AD as measured by Jansen et al.¹⁵ – even at a nominal level. 776 This is possibly due to the exclusion of rare variants (MAF < 0.01), and as such future 777 investigation into the role of rare variants in shared risk for depression and AD is warranted. However, the lack of evidence in these analyses versus the observed 778 779 relationship in epidemiological studies suggests the presence of unidentified 780 confounding. The investigation of possible confounding is an important step for future research to help us better understanded the association between depression and 781 782 dementia.

783 While previous studies have shown that the direction of effect in MR can change depending on whether the outcome AD GWAS contains proxy or clinical 784 cases/controls^{38,39}, this study is - to the best of our knowledge - the first to 785 demonstrate a similar effect with genetic correlations. Of the significant genetic 786 correlations we identified, 95% were identified in proxy+clinical or proxy-only AD 787 GWAS. Where two previous studies^{20,22} identified a genetic correlation between 788 depression and AD, it is noticeable that they used the Jansen et al. proxy+clinial AD 789 790 GWAS as their primary outcome. Further, in the study by Harerimana et al.²² sensitivity analysis did not observe a significant genetic correlation using the clinical-791 only GWAS by Kunkle et al.¹⁴. 792

793 Exactly why depression/depression symptoms show differences in genetic 794 correlation between proxy and clinical AD is a matter of interest. It is noted that most 795 individuals with dementia are cared for by a family member while they are still living 796 in the community¹²⁶. Caregivers incur considerable lifestyle changes, emotional 797 stress, and social strain^{127,128} and depression is reported in up to 50% of caregivers for individuals with dementia¹²⁹. As such, the genetic correlations between 798 depression/depression symptoms and proxy-AD may result from increased 799 800 depression risk due to caregiver responsibilities, exacerbated by a genetic risk. However, this would not explain why no genetic correlations were identified with the 801 Bellenguez et al.¹⁷ GWAS despite this study also containing proxy+clinical 802 phenotyping. As mentioned, Bellenguez et al.¹⁷ define proxy cases/controls as a 803 binary phenotype, whereas Wightman et al.¹⁶ and Jansen et al.¹⁵ define proxy 804 805 cases/controls as a continuous phenotype. These phenotyping differences likely

partially explain the differences in the genetic correlation results, given that these AD 806 GWAS all use the same data from the UK Biobank. However, the proxy-only Marioni 807 et al.³⁷ GWAS - with which genetic correlations were also observed - is a meta-808 809 analysis of maternal and paternal AD GWAS where parental age-at-diagnosis/ageof-death is controlled for in the GWAS model, instead of being used for weighting the 810 proxy phenotype prior analysis. Taking this into account, and considering that 811 depression is itself associated with all-cause mortality¹³⁰, it is possible that including 812 age-at-diagnosis/age-of-death in proxy-AD phenotyping induces a form of bias in 813 later cross-trait analyses when the other trait is itself associated with longevity. Further 814 investigation of this issue is required. 815

Nonetheless, conflicting results such as these pose a problem to researchers 816 817 seeking to identify genetic relationships between AD and its risk factors. Large differences in the presence or direction of effects depending on which AD GWAS is 818 819 used to assess associations increases the difficulty in discerning true associations for the purpose of designing interventions. As such, we suggest that future genetic 820 studies examining genetic overlap between AD risk factors and AD conduct primary 821 822 analyses using a clinically ascertained AD phenotype. A range of AD GWAS with different proxy/clinical ascertainment could then be used to examine the consistency 823 824 of results in relation to clinical AD. While this approach would limit researchers to AD GWAS with slightly smaller sample sizes for primary analyses, it would also ensure 825 that results are driven not by AD proxy phenotyping alone. 826

827 This study has several limitations. Despite being the largest meta-analysis of PHQ-9 items to date, the ability to detect genome-wide significant variants was likely 828 829 limited by small sample sizes relative to other psychiatric conditions. This includes 830 depression itself, where sample sizes have exceeded one million¹³. Larger samples 831 are required for future studies if we are to truly elucidate the unique genetic architecture of individual depression symptoms. Additionally, our analyses were 832 restricted to individuals of European ancestry. GWAS results may therefore have poor 833 834 transferability to other ancestry groups. Although efforts are underway to address the issue of lack of diversity in human genetic studies, urgency is required so that studies 835 can be conducted across ancestry groups using equivalent sample sizes. Our study 836 makes also heavy use of data from the UKB. The UKB is known to be affected by 837 healthy volunteer bias, and as a consequence is not fully representative of the wider 838 839 population¹³¹.

840 It is worth noting that this study focused on depression as a risk factor for AD. 841 However, there is evidence that some forms of later life depression are in fact a 842 prodromal phase of dementia onset^{8,132}, and may be related to levels of dementia 843 biomarkers such as plasma A β 42 and CSF p-tau¹³³. As such, dementia-related 844 depression may be biologically distinct from depression as a mental health disorder. While sufficient sample sizes are likely difficult to obtain, future large scale genomic
studies of dementia-related depression – as has been undertaken with psychosis in
AD¹³⁴ – would prove illuminating on this matter.

In conclusion, this study describes the largest genome-wide meta-analysis of 848 PHQ-9 depression symptom items to date (GWAS equivalent N range: 224,535 -849 308,421), identifying 37 unique genomic risk loci. Genetic correlations between 850 depression/depression symptoms and AD were primarily observed when the AD 851 GWAS contained clinical+proxy or proxy-only AD case/control ascertainment. 852 Further, this study does not support depression or its symptoms as being causal for 853 AD. However, colocalisation in the *TMEM106B* region between four depression 854 phenotypes and AD across both proxy and clinical AD GWAS suggests future 855 856 research into the shared biological mechanisms underlying the role of this locus in depression and AD are warranted. 857

858

859860 5. Funding and Acknowledgements

LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training
and the Perron Institute for Neurological and Translational. PP is funded by
Alzheimer's Research UK. SK is funded by MSWA and the Perron Institute. HLD
acknowledges funding from the Economic and Social Research Council (ESRC).
DMH is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference
213674/Z/18/Z).

868

This paper represents independent research part-funded by the NIHR Maudsley
Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
and King's College London. The views expressed are those of the author(s) and not
necessarily those of the NIHR or the Department of Health and Social Care.

873

This research has been conducted using the UK Biobank Resource underApplication Number 18177. We thank the UK Biobank Team for collecting the dataand making it available. We also thank the UK Biobank participants.

877

We thank the GLAD Study volunteers for their participation, and gratefully 878 879 acknowledge the NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and 880 Transplant, and Health Data Research UK as part of the Digital Innovation Hub 881 Programme. This study presents independent research funded by the NIHR 882 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust 883 King's 884 and College London. Further information can be found at

- http://brc.slam.nhs.uk/about/core-facilities/bioresource. The views expressed are
 those of the authors and not necessarily those of the NHS, the NIHR, the HSC R&D
 Division, King's College London, or the Department of Health and Social Care.
- 888

The PROTECT study was funded/supported by the National Institute of Health and
Care Research Exeter Biomedical Research Centre. PROTECT genetic data was
funded in part by the University of Exeter through the MRC Proximity to Discovery:
Industry Engagement Fund (External Collaboration, Innovation and Entrepreneurism:
Translational Medicine in Exeter 2 (EXCITEME2) ref. MC_PC_17189). Genotyping was
performed at deCODE Genetics. The views expressed are those of the author(s) and
not necessarily those of the NIHR or the Dept of Health and Social Care.

896

As data used in this study was obtained from the ADNI database, the ADNI investigators contributed to the conception of the sample and acquisition of this data, although were not participants in other parts of this study, such as conceptualisation, data analysis or writing. A full acknowledgment list of ADNI investigators can be found at: <u>https://adni.loni.usc.edu/wp-</u>

- 902 <u>content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</u>
- 903

904 Similarly, data was obtained from the GERAD1 Consortium and GERAD1
905 investigators contributed to the conception of the cohort and acquisition of this data,
906 but did not participate in the conceptualisation, analysis or writing of this study. A full

- 907 list of GERAD1 collaborators can be found in **Supplementary Material 1**.
- 908

We also thank and acknowledge the contribution and use of the CREATE highperformance computing cluster at King's College London (King's College London.
(2022). King's Computational Research, Engineering and Technology Environment
(CREATE). Retrieved May 23, 2023, from https://doi.org/10.18742/rnvf-m076).

- 913
- 914 The analysis flowchart in Figure 1. was created and licenced with BioRender915 (www.biorender.com)
- 916
- 917 6. Conflicts of Interest
- 918 CML is on the Scientific Advisory Board of Myriad Neuroscience and has received919 honoraria for consultancy from UCB.
- 920

921 7. Data availability

922 All GWAS summary statistics generated in the process of conducting this study will923 be deposited in the NHGRI-EBI Catalog of human genome-wide association studies

924	(GWAS Cat	talog) following	peer-review and p	oublication. This study was	pre-registered
925	on	the	Open	Science	Framework
926	(https://osf.	<u>io/94q35/?view</u>	only=e77f72d41	00d47eea7f3ef07dfa9c05	<u>9</u>).
927					
928	This study	made use of pu	ıblicly available aı	nalysis software:	
929					
930	MungeSum	nstats			
931	(https://neu	<u>irogenomics.git</u>	hub.io/MungeSur	nstats/articles/MungeSum	<u>stats.html</u>)
932					
933	REGENIE (https://rgcgithu	b.github.io/regen	<u>e/</u>)	
934					
935	MTAG (<u>http</u>	os://github.com,	/JonJala/mtag)		
936					
937	METAL (<u>htt</u>	ps://genome.sp	<u>oh.umich.edu/wiki</u>	METAL Documentation)	
938					
939	FUMA GW	AS (<u>https://fuma</u>	<u>a.ctglab.nl</u>)		
940					
941	LDSC (<u>http</u>	s://github.com/	<u>bulik/ldsc</u>)		
942					
943	HDL (<u>https</u>	://github.com/zl	<u>nenin/HDL)</u>		
944					
945	LAVA (<u>http</u>	<u>s://github.com/j</u>	osefin-werme/LA	<u>/A</u>)	
946					
947	susieR (<u>htt</u>	os://stephensla	b.github.io/susieF	<u>l/index.html</u>)	
948					
949	coloc (<u>http</u>	s://chr1swallace	e.github.io/coloc/)		
950					
951	COLOC-re	porter (<u>https://g</u>	ithub.com/Thoma	sPSpargo/COLOC-reporte	<u>er</u>)
952					
953	CAUSE (<u>ht</u>	tps://jean997.gi	thub.io/cause/ind	<u>ex.html</u>)	
954					
955	TwoSample	eMR (<u>https://mr</u>	cieu.github.io/Two	<u>SampleMR/</u>)	
956					
957	MegaPRS	<u>https://dougspo</u>	eed.com/megapre	<u>5/</u>)	
958					

959 References

- 960
- 1. Byers, A.L., and Yaffe, K. (2011). Depression and risk of developing dementia. Nat. Rev. 961 Neurol. 7, 323–331.
- 962
- 963 2. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne,
- C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020). Dementia prevention, 964
- intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413-446. 965
- 966 3. Yu, O.-C., Jung, B., Go, H., Park, M., and Ha, I.-H. (2020). Association between dementia
- 967 and depression: a retrospective study using the Korean National Health Insurance Service-
- National Sample Cohort database. BMJ Open 10, e034924. 968
- 969 4. Yang, W., Li, X., Pan, K.-Y., Yang, R., Song, R., Qi, X., Pedersen, N.L., and Xu, W.
- 970 (2021). Association of life-course depression with the risk of dementia in late life: A
- 971 nationwide twin study. Alzheimers Dement. 17, 1383-1390.
- 972 5. Richmond-Rakerd, L.S., D'Souza, S., Milne, B.J., Caspi, A., and Moffitt, T.E. (2022).
- Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of 1.7 973
- 974 Million New Zealand Citizens. JAMA Psychiatry 79, 333-340.
- 975 6. Yang, L., Deng, Y.-T., Leng, Y., Ou, Y.-N., Li, Y.-Z., Chen, S.-D., He, X.-Y., Wu, B.-S.,
- Huang, S.-Y., Zhang, Y.-R., et al. (2022). Depression, depression treatments, and risk of 976
- 977 incident dementia: A prospective cohort study of 354,313 participants. Biol. Psychiatry.
- 978 7. GBD 2016 Dementia Collaborators (2019). Global, regional, and national burden of
- Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global 979 Burden of Disease Study 2016. Lancet Neurol. 18, 88-106. 980
- 981 8. Dafsari, F.S., and Jessen, F. (2020). Depression-an underrecognized target for prevention 982 of dementia in Alzheimer's disease. Transl. Psychiatry 10, 160.
- 9. Corfield, E.C., Yang, Y., Martin, N.G., and Nyholt, D.R. (2017). A continuum of genetic 983 liability for minor and major depression. Transl. Psychiatry 7, e1131. 984
- 985 10. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske,
- A., and Pedersen, N.L. (2006). Role of genes and environments for explaining Alzheimer 986 987 disease. Arch. Gen. Psychiatry 63, 168-174.
- 988 11. Wray, N.R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E.M., Abdellaoui, A.,
- Adams, M.J., Agerbo, E., Air, T.M., Andlauer, T.M.F., et al. (2018). Genome-wide 989
- 990 association analyses identify 44 risk variants and refine the genetic architecture of major 991 depression. Nat. Genet. 50, 668-681.
- 12. Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M., 992
- 993 Coleman, J.R.I., Hagenaars, S.P., Ward, J., Wigmore, E.M., et al. (2019). Genome-wide
- 994 meta-analysis of depression identifies 102 independent variants and highlights the importance
- 995 of the prefrontal brain regions. Nat. Neurosci. 22, 343-352.
- 13. Levey, D.F., Stein, M.B., Wendt, F.R., Pathak, G.A., Zhou, H., Aslan, M., Quaden, R., 996
- 997 Harrington, K.M., Nuñez, Y.Z., Overstreet, C., et al. (2021). Bi-ancestral depression GWAS
- 998 in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new 999 therapeutic directions. Nat. Neurosci. 24, 954–963.
- 14. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., 1000
- 1001 Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of
- 1002 diagnosed Alzheimer's disease identifies new risk loci and implicates AB, tau, immunity and 1003 lipid processing. Nat. Genet. 51, 414–430.
- 1004 15. Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S.,
- 1005 Sealock, J., Karlsson, I.K., Hägg, S., Athanasiu, L., et al. (2019). Genome-wide meta-analysis
- 1006 identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat. Genet. 51, 404–413. 1007
- 16. Wightman, D.P., Jansen, I.E., Savage, J.E., Shadrin, A.A., Bahrami, S., Holland, D., 1008

- 1009 Rongve, A., Børte, S., Winsvold, B.S., Drange, O.K., et al. (2021). A genome-wide
- 1010 association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. 1011 Nat. Genet. 53, 1276-1282.
- 1012 17. Bellenguez, C., Küçükali, F., Jansen, I.E., Kleineidam, L., Moreno-Grau, S., Amin, N.,
- 1013 Naj, A.C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022). New insights
- 1014 into the genetic etiology of Alzheimer's disease and related dementias. Nat. Genet. 54, 412– 1015 436.
- 1016 18. Gibson, J., Russ, T.C., Adams, M.J., Clarke, T.K., Howard, D.M., Hall, L.S., Fernandez-
- Pujals, A.M., Wigmore, E.M., Hayward, C., Davies, G., et al. (2017). Assessing the presence 1017
- of shared genetic architecture between Alzheimer's disease and major depressive disorder 1018
- 1019 using genome-wide association data. Transl. Psychiatry 7, e1094.
- 1020 19. Andrews, S.J., Fulton-Howard, B., O'Reilly, P., Marcora, E., Goate, A.M., and
- 1021 collaborators of the Alzheimer's Disease Genetics Consortium (2021). Causal associations
- 1022 between modifiable risk factors and the alzheimer's phenome. Ann. Neurol. 89, 54-65.
- 1023 20. Santos, F.C.D., Mendes-Silva, A.P., Nikolova, Y.C., Sibille, E., and Diniz, B.S. (2021).
- 1024 Genetic overlap between major depression, bipolar disorder and Alzheimer's Disease. 1025 MedRxiv.
- 21. Monereo-Sánchez, J., Schram, M.T., Frei, O., O'Connell, K., Shadrin, A.A., Smeland, 1026
- O.B., Westlye, L.T., Andreassen, O.A., Kaufmann, T., Linden, D.E.J., et al. (2021). Genetic 1027
- 1028 overlap between alzheimer's disease and depression mapped onto the brain. Front. Neurosci. 1029 15,653130.
- 1030 22. Harerimana, N.V., Liu, Y., Gerasimov, E.S., Duong, D., Beach, T.G., Reiman, E.M.,
- 1031 Schneider, J.A., Boyle, P., Lori, A., Bennett, D.A., et al. (2022). Genetic evidence supporting a causal role of depression in alzheimer's disease. Biol. Psychiatry 92, 25-33.
- 1032
- 1033 23. American Psychiatric Association (2013). Depressive Disorders. In Diagnostic and
- 1034 Statistical Manual of Mental Disorders, (American Psychiatric Association), p.
- 1035 24. Fried, E.I., and Nesse, R.M. (2015). Depression is not a consistent syndrome: An
- 1036 investigation of unique symptom patterns in the STAR*D study. J. Affect. Disord. 172, 96-1037 102.
- 1038 25. Zimmerman, M., Ellison, W., Young, D., Chelminski, I., and Dalrymple, K. (2015). How 1039 many different ways do patients meet the diagnostic criteria for major depressive disorder? 1040 Compr. Psychiatry 56, 29-34.
- 26. Park, S.-C., Kim, J.-M., Jun, T.-Y., Lee, M.-S., Kim, J.-B., Yim, H.-W., and Park, Y.C. 1041
- 1042 (2017). How many different symptom combinations fulfil the diagnostic criteria for major
- 1043 depressive disorder? Results from the CRESCEND study. Nord J Psychiatry 71, 217–222.
- 1044 27. Cai, N., Choi, K.W., and Fried, E.I. (2020). Reviewing the genetics of heterogeneity in
- 1045 depression: operationalizations, manifestations and etiologies. Hum. Mol. Genet. 29, R10-1046 R18.
- 1047 28. Nguyen, T.-D., Harder, A., Xiong, Y., Kowalec, K., Hägg, S., Cai, N., Kuja-Halkola, R.,
- 1048 Dalman, C., Sullivan, P.F., and Lu, Y. (2022). Genetic heterogeneity and subtypes of major 1049 depression. Mol. Psychiatry 27, 1667–1675.
- 1050 29. Thorp, J.G., Marees, A.T., Ong, J.-S., An, J., MacGregor, S., and Derks, E.M. (2020).
- Genetic heterogeneity in self-reported depressive symptoms identified through genetic 1051
- analyses of the PHQ-9. Psychol. Med. 50, 2385-2396. 1052
- 1053 30. So, Y., Kim, K.W., Park, J.H., Lee, J.J., Lee, S.B., and TaeHui Kim (2012). P3-396:
- 1054 Anhedonia is associated with the risk of Alzheimer's disease in elders with mild cognitive
- 1055 impairment: Results from the Korean Longitudinal Study on Health and Aging (KLOSHA). 1056 Alzheimers Dement. 8, P594–P594.
- 1057 31. Lee, J.R., Suh, S.W., Han, J.W., Byun, S., Kwon, S.J., Lee, K.H., Kwak, K.P., Kim, B.J.,
- 1058 Kim, S.G., Kim, J.L., et al. (2019). Anhedonia and Dysphoria Are Differentially Associated

- with the Risk of Dementia in the Cognitively Normal Elderly Individuals: A ProspectiveCohort Study. Psychiatry Investig *16*, 575–580.
- 1061 32. Vaquero-Puyuelo, D., De-la-Cámara, C., Olaya, B., Gracia-García, P., Lobo, A., López-
- 1062 Antón, R., and Santabárbara, J. (2021). Anhedonia as a Potential Risk Factor of Alzheimer's
- 1063 Disease in a Community-Dwelling Elderly Sample: Results from the ZARADEMP Project.
- 1064 Int. J. Environ. Res. Public Health 18,.
- 1065 33. Ikeda, M., Brown, J., Holland, A.J., Fukuhara, R., and Hodges, J.R. (2002). Changes in
- appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's
- 1067 disease. J. Neurol. Neurosurg. Psychiatry 73, 371–376.
- 1068 34. Bailon, O., Roussel, M., Boucart, M., Krystkowiak, P., and Godefroy, O. (2010).
- 1069 Psychomotor slowing in mild cognitive impairment, Alzheimer's disease and lewy body
- 1070 dementia: mechanisms and diagnostic value. Dement. Geriatr. Cogn. Disord. 29, 388–396.
- 1071 35. Koren, T., Fisher, E., Webster, L., Livingston, G., and Rapaport, P. (2022). Prevalence of
- 1072 sleep disturbances in people with dementia living in the community: A systematic review and1073 meta-analysis. Ageing Res Rev 101782.
- 36. Escott-Price, V., and Hardy, J. (2022). Genome-wide association studies for Alzheimer's
 disease: bigger is not always better. Brain Commun. *4*, fcac125.
- 1076 37. Marioni, R.E., Harris, S.E., Zhang, Q., McRae, A.F., Hagenaars, S.P., Hill, W.D., Davies,
- 1077 G., Ritchie, C.W., Gale, C.R., Starr, J.M., et al. (2018). GWAS on family history of
- 1078 Alzheimer's disease. Transl. Psychiatry 8, 99.
- 1079 38. Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B.-L.,
- and Liu, G. (2022). Mendelian randomization highlights significant difference and genetic
 heterogeneity in clinically diagnosed Alzheimer's disease GWAS and self-report proxy
- 1082 phenotype GWAX. Alzheimers Res. Ther. 14, 17.
- 1083 39. Desai, R., John, A., Saunders, R., Marchant, N.L., Buckman, J.E.J., Charlesworth, G.,
- Zuber, V., and Stott, J. (2023). Examining the Lancet Commission risk factors for dementia
 using Mendelian randomisation. BMJ Ment Health 26,.
- 1086 40. European Alzheimer's & Dementia Biobank Mendelian Randomization (EADB-MR)
- 1087 Collaboration, Luo, J., Thomassen, J.Q., Bellenguez, C., Grenier-Boley, B., de Rojas, I.,
- 1088 Castillo, A., Parveen, K., Küçükali, F., Nicolas, A., et al. (2023). Genetic associations
- 1089 between modifiable risk factors and alzheimer disease. JAMA Netw. Open 6, e2313734.
- 1090 41. Davies, M.R., Kalsi, G., Armour, C., Jones, I.R., McIntosh, A.M., Smith, D.J., Walters,
- 1091 J.T.R., Bradley, J.R., Kingston, N., Ashford, S., et al. (2019). The Genetic Links to Anxiety
- and Depression (GLAD) Study: Online recruitment into the largest recontactable study of
 depression and anxiety. Behav. Res. Ther. *123*, 103503.
- 1094 42. Creese, B., Arathimos, R., Brooker, H., Aarsland, D., Corbett, A., Lewis, C., Ballard, C.,
- and Ismail, Z. (2021). Genetic risk for Alzheimer's disease, cognition, and mild behavioral
- 1096 impairment in healthy older adults. Alzheimers Dement (Amst) 13, e12164.
- 1097 43. Arathimos, R., Fabbri, C., Vassos, E., Davis, K.A.S., Pain, O., Gillett, A., Coleman,
- 1098 J.R.I., Hanscombe, K., Hagenaars, S., Jermy, B., et al. (2022). Latent subtypes of manic
- and/or irritable episode symptoms in two population-based cohorts. Br. J. Psychiatry 221,
 722–731.
- 1101 44. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
- 1102 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep 1103 phenotyping and genomic data. Nature *562*, 203–209.
- 1104 45. Wightman, D.P., Savage, J.E., Tissink, E., Romero, C., Jansen, I.E., and Posthuma, D.
- 1105 (2023). The genetic overlap between Alzheimer's disease, amyotrophic lateral sclerosis,
- 1106 Lewy body dementia, and Parkinson's disease. Neurobiol. Aging.
- 1107 46. Kroenke, K., Spitzer, R.L., and Williams, J.B. (2001). The PHQ-9: validity of a brief
- depression severity measure. J. Gen. Intern. Med. 16, 606–613.

- 1109 47. Sun, Y., Fu, Z., Bo, Q., Mao, Z., Ma, X., and Wang, C. (2020). The reliability and
- validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital. BMCPsychiatry 20, 474.
- 1112 48. Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A.,
- 1113 Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2021). Computationally
- 1114 efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097–
- 1115 1103.
- 1116 49. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015).
- Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience4, 7.
- 50. Privé, F., Luu, K., Blum, M.G.B., McGrath, J.J., and Vilhjálmsson, B.J. (2020). Efficient
 toolkit implementing best practices for principal component analysis of population genetic
 data. Bioinformatics *36*, 4449–4457.
- 1122 51. McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang,
- 1123 H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976
- haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283.
- 1125 52. Chou, W.-C., Zheng, H.-F., Cheng, C.-H., Yan, H., Wang, L., Han, F., Richards, J.B.,
- 1126 Karasik, D., Kiel, D.P., and Hsu, Y.-H. (2016). A combined reference panel from the
- 1127 1000 Genomes and UK10K projects improved rare variant imputation in European and1128 Chinese samples. Sci. Rep. *6*, 39313.
- 1129 53. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun,
- 1130 S.A.G., Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831
- diverse genomes from the NHLBI TOPMed Program. Nature *590*, 290–299.
- 1132 54. 1000 Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison,
- 1133 E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., et al. (2015). A
- 1134 global reference for human genetic variation. Nature *526*, 68–74.
- 1135 55. Murphy, A.E., Schilder, B.M., and Skene, N.G. (2021). MungeSumstats: A Bioconductor
- package for the standardisation and quality control of many GWAS summary statistics.Bioinformatics.
- 1138 56. Bulik-Sullivan, B., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia
- 1139 Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M.J., Price,
- 1140 A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from
- 1141 polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295.
- 1142 57. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R.,
- 1143 ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia
- 1144 Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan, L., et al. (2015). An
- atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241.
- 58. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis
 of genomewide association scans. Bioinformatics 26, 2190–2191.
- 1148 59. Turley, P., Walters, R.K., Maghzian, O., Okbay, A., Lee, J.J., Fontana, M.A., Nguyen-
- 1149 Viet, T.A., Wedow, R., Zacher, M., Furlotte, N.A., et al. (2018). Multi-trait analysis of
- 1150 genome-wide association summary statistics using MTAG. Nat. Genet. 50, 229–237.
- 1151 60. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional
- 1152 mapping and annotation of genetic associations with FUMA. Nat. Commun. *8*, 1826.
- 1153 61. Jaffe, A.E., Straub, R.E., Shin, J.H., Tao, R., Gao, Y., Collado-Torres, L., Kam-Thong,
- 1154 T., Xi, H.S., Quan, J., Chen, Q., et al. (2018). Developmental and genetic regulation of the
- human cortex transcriptome illuminate schizophrenia pathogenesis. Nat. Neurosci. 21, 1117–
 1125.
- 1157 62. Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F.C.P., Clarke, D., Gu, M.,
- 1158 Emani, P., Yang, Y.T., et al. (2018). Comprehensive functional genomic resource and

- 1159 integrative model for the human brain. Science 362,.
- 1160 63. Fromer, M., Roussos, P., Sieberts, S.K., Johnson, J.S., Kavanagh, D.H., Perumal, T.M.,
- 1161 Ruderfer, D.M., Oh, E.C., Topol, A., Shah, H.R., et al. (2016). Gene expression elucidates
- 1162 functional impact of polygenic risk for schizophrenia. Nat. Neurosci. 19, 1442–1453.
- 1163 64. Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De, T., UK
- 1164 Brain Expression Consortium, North American Brain Expression Consortium, Coin, L., et al.
- 1165 (2014). Genetic variability in the regulation of gene expression in ten regions of the human
- 1166 brain. Nat. Neurosci. 17, 1418–1428.
- 1167 65. Westra, H.-J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J.,
- 1168 Christiansen, M.W., Fairfax, B.P., Schramm, K., Powell, J.E., et al. (2013). Systematic
- identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet.45, 1238–1243.
- 1171 66. Zhernakova, D.V., Deelen, P., Vermaat, M., van Iterson, M., van Galen, M., Arindrarto,
- 1172 W., van 't Hof, P., Mei, H., van Dijk, F., Westra, H.-J., et al. (2017). Identification of context-
- dependent expression quantitative trait loci in whole blood. Nat. Genet. 49, 139–145.
- 1174 67. Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
- Saha, A., Kreuzhuber, R., Kasela, S., et al. (2018). Unraveling the polygenic architecture ofcomplex traits using blood eQTL meta-analysis. BioRxiv.
- 1177 68. Buil, A., Brown, A.A., Lappalainen, T., Viñuela, A., Davies, M.N., Zheng, H.-F.,
- 1178 Richards, J.B., Glass, D., Small, K.S., Durbin, R., et al. (2015). Gene-gene and gene-
- environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet.
 47, 88–91.
- 1181 69. Ng, B., White, C.C., Klein, H.-U., Sieberts, S.K., McCabe, C., Patrick, E., Xu, J., Yu, L.,
- 1182 Gaiteri, C., Bennett, D.A., et al. (2017). An xQTL map integrates the genetic architecture of
- the human brain's transcriptome and epigenome. Nat. Neurosci. 20, 1418–1426.
- 1184 70. van Rheenen, W., Peyrot, W.J., Schork, A.J., Lee, S.H., and Wray, N.R. (2019). Genetic
- correlations of polygenic disease traits: from theory to practice. Nat. Rev. Genet. 20, 567–
 581.
- 1187 71. Ning, Z., Pawitan, Y., and Shen, X. (2020). High-definition likelihood inference of
 1188 genetic correlations across human complex traits. Nat. Genet. *52*, 859–864.
- 1189 72. Werme, J., van der Sluis, S., Posthuma, D., and de Leeuw, C.A. (2022). An integrated
 1190 framework for local genetic correlation analysis. Nat. Genet. 54, 274–282.
- 1191 73. Spargo, T.P., Gilchrist, L., Hunt, G.P., Dobson, R.J., Proitsi, P.P., Al-Chalabi, A., Pain,
- 1192 O., and Iacoangeli, A. (2023). Statistical examination of shared loci in neuropsychiatric
- 1193 diseases using genome-wide association study summary statistics. MedRxiv.
- 1194 74. Zou, Y., Carbonetto, P., Wang, G., and Stephens, M. (2022). Fine-mapping from
- summary data with the "Sum of Single Effects" model. PLoS Genet. 18, e1010299.
- 1196 75. Wallace, C. (2021). A more accurate method for colocalisation analysis allowing for
- 1197 multiple causal variants. PLoS Genet. 17, e1009440.
- 1198 76. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace,
- 1199 C., and Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic
- association studies using summary statistics. PLoS Genet. 10, e1004383.
- 1201 77. Sanderson, E., Glymour, M.M., Holmes, M.V., Kang, H., Morrison, J., Munafò, M.R.,
- Palmer, T., Schooling, C.M., Wallace, C., Zhao, Q., et al. (2022). Mendelian randomization.
 Nat. Rev. Methods Primers 2, 6.
- 1204 78. Burgess, S., Davies, N.M., and Thompson, S.G. (2016). Bias due to participant overlap in
 1205 two-sample Mendelian randomization. Genet. Epidemiol. 40, 597–608.
- 1206 79. Morrison, J., Knoblauch, N., Marcus, J.H., Stephens, M., and He, X. (2020). Mendelian
- 1207 randomization accounting for correlated and uncorrelated pleiotropic effects using genome-
- 1208 wide summary statistics. Nat. Genet. *52*, 740–747.

- 1209 80. Hemani, G., Bowden, J., and Davey Smith, G. (2018). Evaluating the potential role of
- 1210 pleiotropy in Mendelian randomization studies. Hum. Mol. Genet. 27, R195–R208.
- 1211 81. Slob, E.A.W., and Burgess, S. (2020). A comparison of robust Mendelian randomization
 1212 methods using summary data. Genet. Epidemiol. 44, 313–329.
- 1213 82. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with
- 1214 invalid instruments: effect estimation and bias detection through Egger regression. Int. J.
- **1215** Epidemiol. *44*, 512–525.
- 1216 83. Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016). Consistent
- 1217 Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted
 1218 Median Estimator. Genet. Epidemiol. 40, 304–314.
- 1219 84. Hartwig, F.P., Davey Smith, G., and Bowden, J. (2017). Robust inference in summary
- data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol.
 46, 1985–1998.
- 1222 85. Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread
- horizontal pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. Nat. Genet. 50, 693–698.
- 1225 86. Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian
- randomization using the MR-Egger method. Eur J Epidemiol *32*, 377–389.
- 1227 87. Burgess, S., Bowden, J., Fall, T., Ingelsson, E., and Thompson, S.G. (2017). Sensitivity
- Analyses for Robust Causal Inference from Mendelian Randomization Analyses with
 Multiple Genetic Variants. Epidemiology 28, 30–42.
- 1230 88. Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N., and Davey Smith, G. (2008).
- 1231 Mendelian randomization: using genes as instruments for making causal inferences in
- 1232 epidemiology. Stat. Med. 27, 1133–1163.
- 1233 89. Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N.A., and
- 1234 Thompson, J.R. (2016). Assessing the suitability of summary data for two-sample Mendelian
- randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J.
 Epidemiol. 45, 1961–1974.
- 1237 90. Mahley, R.W. (2016). Apolipoprotein E: from cardiovascular disease to
- 1238 neurodegenerative disorders. J. Mol. Med. 94, 739–746.
- 1239 91. Liu, S., Liu, J., Weng, R., Gu, X., and Zhong, Z. (2019). Apolipoprotein E gene
- polymorphism and the risk of cardiovascular disease and type 2 diabetes. BMC Cardiovasc.Disord. 19, 213.
- 1242 92. Xuan, L., Zhao, Z., Jia, X., Hou, Y., Wang, T., Li, M., Lu, J., Xu, Y., Chen, Y., Qi, L., et
- al. (2018). Type 2 diabetes is causally associated with depression: a Mendelian randomizationanalysis. Front Med *12*, 678–687.
- 1245 93. Lu, Y., Wang, Z., Georgakis, M.K., Lin, H., and Zheng, L. (2021). Genetic liability to
- 1246 depression and risk of coronary artery disease, myocardial infarction, and other
- 1247 cardiovascular outcomes. J. Am. Heart Assoc. 10, e017986.
- 1248 94. Lord, J., Jermy, B., Green, R., Wong, A., Xu, J., Legido-Quigley, C., Dobson, R.,
- 1249 Richards, M., and Proitsi, P. (2021). Mendelian randomization identifies blood metabolites
- previously linked to midlife cognition as causal candidates in Alzheimer's disease. Proc.Natl. Acad. Sci. USA *118*,.
- 1252 95. Choi, S.W., Mak, T.S.-H., and O'Reilly, P.F. (2020). Tutorial: a guide to performing
- 1253 polygenic risk score analyses. Nat. Protoc. 15, 2759–2772.
- 1254 96. Zhang, Q., Privé, F., Vilhjálmsson, B., and Speed, D. (2021). Improved genetic prediction
- 1255 of complex traits from individual-level data or summary statistics. Nat. Commun. 12, 4192.
- 1256 97. Lovestone, S., Francis, P., Kloszewska, I., Mecocci, P., Simmons, A., Soininen, H.,
- 1257 Spenger, C., Tsolaki, M., Vellas, B., Wahlund, L.-O., et al. (2009). AddNeuroMed--the
- 1258 European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann.

- 1259 N. Y. Acad. Sci. 1180, 36–46.
- 1260 98. Lord, J., Green, R., Choi, S.W., Hübel, C., Aarsland, D., Velayudhan, L., Sham, P.,
- 1261 Legido-Quigley, C., Richards, M., Dobson, R., et al. (2022). Disentangling independent and
- mediated causal relationships between blood metabolites, cognitive factors, and alzheimer's
 disease. Biological Psychiatry Global Open Science 2, 167–179.
- 1264 99. Yang, J., Weedon, M.N., Purcell, S., Lettre, G., Estrada, K., Willer, C.J., Smith, A.V.,
- 1265 Ingelsson, E., O'Connell, J.R., Mangino, M., et al. (2011). Genomic inflation factors under
- 1266 polygenic inheritance. Eur. J. Hum. Genet. 19, 807–812.
- 1267 100. Voskobiynyk, Y., Roth, J.R., Cochran, J.N., Rush, T., Carullo, N.V., Mesina, J.S.,
- Waqas, M., Vollmer, R.M., Day, J.J., McMahon, L.L., et al. (2020). Alzheimer's disease risk
 gene BIN1 induces Tau-dependent network hyperexcitability. Elife 9.
- 1270 101. Lambert, E., Saha, O., Soares Landeira, B., Melo de Farias, A.R., Hermant, X., Carrier,
- 1271 A., Pelletier, A., Gadaut, J., Davoine, L., Dupont, C., et al. (2022). The Alzheimer
- susceptibility gene BIN1 induces isoform-dependent neurotoxicity through early endosomedefects. Acta Neuropathol. Commun. *10*, 4.
- 1274 102. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P.,
- 1275 Boehnke, M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of 1276 genome-wide association scan results. Bioinformatics *26*, 2336–2337.
- 1277 103. Dashti, H.S., Daghlas, I., Lane, J.M., Huang, Y., Udler, M.S., Wang, H., Ollila, H.M.,
- Jones, S.E., Kim, J., Wood, A.R., et al. (2021). Genetic determinants of daytime napping andeffects on cardiometabolic health. Nat. Commun. *12*, 900.
- 1280 104. Jansen, P.R., Watanabe, K., Stringer, S., Skene, N., Bryois, J., Hammerschlag, A.R., de
- 1281 Leeuw, C.A., Benjamins, J.S., Muñoz-Manchado, A.B., Nagel, M., et al. (2019). Genome-
- wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional
 pathways. Nat. Genet. *51*, 394–403.
- 1284 105. Hammerschlag, A.R., Stringer, S., de Leeuw, C.A., Sniekers, S., Taskesen, E.,
- 1285 Watanabe, K., Blanken, T.F., Dekker, K., Te Lindert, B.H.W., Wassing, R., et al. (2017).
- 1286 Genome-wide association analysis of insomnia complaints identifies risk genes and genetic
- 1287 overlap with psychiatric and metabolic traits. Nat. Genet. 49, 1584–1592.
- 1288 106. Loos, R.J.F., and Yeo, G.S.H. (2022). The genetics of obesity: from discovery to
- 1289 biology. Nat. Rev. Genet. 23, 120–133.
- 1290 107. Zarza-Rebollo, J.A., Molina, E., and Rivera, M. (2021). The role of the FTO gene in the
- relationship between depression and obesity. A systematic review. Neurosci. Biobehav. Rev. *127*, 630–637.
- 1293 108. González, L.M., García-Herráiz, A., Mota-Zamorano, S., Flores, I., Albuquerque, D.,
- and Gervasini, G. (2021). Variants in the Obesity-Linked FTO gene locus modulates
- 1295 psychopathological features of patients with Anorexia Nervosa. Gene 783, 145572.
- 1296 109. Li, Y., Dang, X., Chen, R., Wang, J., Li, S., Mitchell, B.L., Yao, Y.-G., Li, M., Li, T.,
- 1297 Zhang, Z., et al. (2023). Cross-ancestry genome-wide association study and systems-level
- integrative analyses implicate new risk genes and therapeutic targets for depression.MedRxiv.
- 1300 110. Dall'Aglio, L., Lewis, C.M., and Pain, O. (2021). Delineating the genetic component of
 1301 gene expression in major depression. Biol. Psychiatry *89*, 627–636.
- 1302 111. Fabbri, C., Pain, O., Hagenaars, S.P., Lewis, C.M., and Serretti, A. (2021).
- 1303 Transcriptome-wide association study of treatment-resistant depression and depression
- 1304 subtypes for drug repurposing. Neuropsychopharmacology *46*, 1821–1829.
- 1305 112. Koskinen, M.-K., and Hovatta, I. (2023). Genetic insights into the neurobiology of
- 1306 anxiety. Trends Neurosci. *46*, 318–331.
- 1307 113. Nagel, M., Jansen, P.R., Stringer, S., Watanabe, K., de Leeuw, C.A., Bryois, J., Savage,
- 1308 J.E., Hammerschlag, A.R., Skene, N.G., Muñoz-Manchado, A.B., et al. (2018). Meta-analysis

- of genome-wide association studies for neuroticism in 449,484 individuals identifies novel
 genetic loci and pathways. Nat. Genet. 50, 920–927.
- 1311 114. Mallard, T.T., Linnér, R.K., Grotzinger, A.D., Sanchez-Roige, S., Seidlitz, J., Okbay,
- 1312 A., de Vlaming, R., Meddens, S.F.W., Bipolar Disorder Working Group of the Psychiatric
- 1313 Genomics Consortium, Palmer, A.A., et al. (2022). Multivariate GWAS of psychiatric
- disorders and their cardinal symptoms reveal two dimensions of cross-cutting genetic
- 1315 liabilities. Cell Genomics 2,.
- 1316 115. Lüningschrör, P., Werner, G., Stroobants, S., Kakuta, S., Dombert, B., Sinske, D.,
- 1317 Wanner, R., Lüllmann-Rauch, R., Wefers, B., Wurst, W., et al. (2020). The FTLD risk factor
- 1318 TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons.1319 Cell Rep. *30*, 3506–3519.e6.
- 1320 116. Van Deerlin, V.M., Sleiman, P.M.A., Martinez-Lage, M., Chen-Plotkin, A., Wang, L.-
- 1321 S., Graff-Radford, N.R., Dickson, D.W., Rademakers, R., Boeve, B.F., Grossman, M., et al.
- (2010). Common variants at 7p21 are associated with frontotemporal lobar degeneration with
 TDP-43 inclusions. Nat. Genet. 42, 234–239.
- 1324 117. Nicholson, A.M., and Rademakers, R. (2016). What we know about TMEM106B in 1325 neurodegeneration. Acta Neuropathol. *132*, 639–651.
- 1326 118. Feng, T., Lacrampe, A., and Hu, F. (2021). Physiological and pathological functions of
- TMEM106B: a gene associated with brain aging and multiple brain disorders. ActaNeuropathol. *141*, 327–339.
- 1329 119. Perneel, J., and Rademakers, R. (2022). Identification of TMEM106B amyloid fibrils
 1330 provides an updated view of TMEM106B biology in health and disease. Acta Neuropathol.
- **1331** *144*, 807–819.
- 1332 120. Mao, F., Robinson, J.L., Unger, T., Posavi, M., Amado, D.A., Elman, L., Grossman, M.,
- Wolk, D.A., Lee, E.B., Van Deerlin, V.M., et al. (2021). TMEM106B modifies TDP-43
 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta
- 1335 Neuropathol. *142*, 629–642.
- 1336 121. Vass, R., Ashbridge, E., Geser, F., Hu, W.T., Grossman, M., Clay-Falcone, D., Elman,
- 1337 L., McCluskey, L., Lee, V.M.Y., Van Deerlin, V.M., et al. (2011). Risk genotypes at
- 1338 TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta1339 Neuropathol. *121*, 373–380.
- 1340 122. Shafit-Zagardo, B., Sidoli, S., Goldman, J.E., DuBois, J.C., Corboy, J.R., Strittmatter,
- 1341 S.M., Guzik, H., Graff, S., and Nagra, R.M. (2022). TMEM106B is increased in Multiple
- 1342 Sclerosis plaques, and deletion causes accumulation of lipid after demyelination. BioRxiv.
- 1343 123. Hong, S., Dobricic, V., Ohlei, O., Bos, I., Vos, S.J.B., Prokopenko, D., Tijms, B.M.,
- 1344 Andreasson, U., Blennow, K., Vandenberghe, R., et al. (2021). TMEM106B and CPOX are
- genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. AlzheimersDement. 17, 1628–1640.
- 1347 124. Dhiman, K., Gupta, V.B., Villemagne, V.L., Eratne, D., Graham, P.L., Fowler, C.,
- 1348 Bourgeat, P., Li, Q.-X., Collins, S., Bush, A.I., et al. (2020). Cerebrospinal fluid
- 1349 neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's
- 1350 disease. Alzheimers Dement (Amst) 12, e12005.
- 1351 125. Chen, M.-H., Liu, Y.-L., Kuo, H.-W., Tsai, S.-J., Hsu, J.-W., Huang, K.-L., Tu, P.-C.,
- and Bai, Y.-M. (2022). Neurofilament light chain is a novel biomarker for major depression
- and related executive dysfunction. Int. J. Neuropsychopharmacol. 25, 99–105.
- 1354 126. Brodaty, H., and Donkin, M. (2009). Family caregivers of people with dementia.
- 1355 Dialogues Clin Neurosci 11, 217–228.
- 1356 127. Lindeza, P., Rodrigues, M., Costa, J., Guerreiro, M., and Rosa, M.M. (2020). Impact of
- 1357 dementia on informal care: a systematic review of family caregivers' perceptions. BMJ
- 1358 Support. Palliat. Care.

- 1359 128. Victor, C.R., Rippon, I., Quinn, C., Nelis, S.M., Martyr, A., Hart, N., Lamont, R., and
- 1360 Clare, L. (2021). The prevalence and predictors of loneliness in caregivers of people with
- dementia: findings from the IDEAL programme. Aging Ment. Health 25, 1232–1238.
- 1362 129. Huang, S.-S. (2022). Depression among caregivers of patients with dementia:
- Associative factors and management approaches. World J. Psychiatry 12, 59–76.
- 1364 130. Chesney, E., Goodwin, G.M., and Fazel, S. (2014). Risks of all-cause and suicide
- 1365 mortality in mental disorders: a meta-review. World Psychiatry 13, 153–160.
- 1366 131. Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins,
- 1367 R., and Allen, N.E. (2017). Comparison of Sociodemographic and Health-Related
- 1368 Characteristics of UK Biobank Participants With Those of the General Population. Am. J.1369 Epidemiol. *186*, 1026–1034.
- 1370 132. Brommelhoff, J.A., Gatz, M., Johansson, B., McArdle, J.J., Fratiglioni, L., and
- 1371 Pedersen, N.L. (2009). Depression as a risk factor or prodromal feature for dementia?
- 1372 Findings in a population-based sample of Swedish twins. Psychol. Aging 24, 373–384.
- 1373 133. Creese, B., and Ismail, Z. (2022). Mild behavioral impairment: measurement and
- 1374 clinical correlates of a novel marker of preclinical Alzheimer's disease. Alzheimers Res.
- 1375 Ther. 14, 2.
- 1376 134. DeMichele-Sweet, M.A.A., Klei, L., Creese, B., Harwood, J.C., Weamer, E.A.,
- 1377 McClain, L., Sims, R., Hernandez, I., Moreno-Grau, S., Tárraga, L., et al. (2021). Genome-
- 1378 wide association identifies the first risk loci for psychosis in Alzheimer disease. Mol.
- 1379 Psychiatry 26, 5797–5811.
- 1380
- 1381
- 1382
- 1383 1384
- 1385